

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

/db_xref="taxon:99883"
 /clone="14P20"
 /note="Genoscope sequence ID : COAG14DH10LPI-end : T7"
 BASE COUNT 12 a 12 c 26 g 34 t 2 others
 ORIGIN

Query Match 64.8%; Score 18.8; DB 12; Length 86;
 Best Local Similarity 50.0%; Pred. No. 4.4e+03;
 Matches 11; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

Qy 6 uuuuuuuuagccuagggg 27
 Db 62 TTCTTTTGTAGGCTAGGG 83

RESULT 2
 AZ786158 96 bp DNA linear GSS 16-FEB-2001
 LOCUS 2M0031E01R Mouse 10kb plasmid UGCM library Mus musculus genomic
 DEFINITION clone UGCM0031E01 R, DNA sequence.
 AZ786158
 VERSION 1 GI:12923638
 KEYWORDS GSS.
 SOURCE house mouse.
 ORGANISM Mus musculus

REFERENCE 1 (bases 1 to 96)
 AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
 Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,
 M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A.
 and Wright,D., Weiss,R.
 Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts

JOURNAL Unpublished (2000)
 COMMENT Contact: Robert B. Weiss
 University of Utah Genome Center
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0031 row: E column: 01
 Seq primer: CACACAGGAACACGATATGACC
 Class: plasmid ends
 High quality sequence stop: 96.

Location/Qualifiers
 1. 96
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UGCM0031E01"
 /sex="Male"
 /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: pMD42ny; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA
 was hydrodynamically sheared by repeated passage through a
 0.005 inch orifice at constant velocity. The sheared DNA
 was blunt end-repaired with T4 DNA polymerase and T4
 polynucleotide kinase. Adaptor oligonucleotides were
 ligated to the blunt ends in high molar excess. The
 adaptor DNA was purified and size-selected for a 9.5 to
 10.5 kb range using preparative agarose gel
 electrophoresis. Vector DNA was prepared from a derivative
 of pMD42 (g14732114|b|AF129072.1), a copy-number
 inducible derivative of plasmid R1. The vector was ligated

with adaptors complementary to the insert adaptors and
 purified. The sheared, adaptor mouse DNA was annealed to
 adaptor vector DNA, and transformed into
 chemically-competent E. coli XL10-Gold (Stratagene) cells
 and selected for ampicillin resistance."
 BASE COUNT 39 a 25 c 19 g 13 t
 ORIGIN

Query Match 56.6%; Score 16.4; DB 12; Length 96;
 Best Local Similarity 42.3%; Pred. No. 3.3e+04;
 Matches 11; Conservative 9; Mismatches 6; Indels 0; Gaps 0;

Qy 4 gaucuuuuuagccuaggggcu 29
 Db 53 GTTCTTTTGGAGCAGCAGGCT 28

RESULT 3
 A1561770 57 bp mRNA linear EST 25-MAR-1999
 LOCUS vv65b08.x1 Stratagene mouse skin (#937313) Mus musculus cDNA clone
 DEFINITION IMAGE:1227255 3', mRNA sequence.
 A1561770
 VERSION 1 GI:4513115
 KEYWORDS EST.
 SOURCE house mouse.
 ORGANISM Mus musculus

REFERENCE 1 (bases 1 to 57)
 AUTHORS Marta,M., Hillier,L., Kucaba,T., Martin,J., Beck,C., Wylie,T.,
 Underwood,K., Steptoe,M., Theising,B., Allen,M., Bowers,Y., Person
 B., Swaller,T., Gibbons,M., Page,D., Harvey,N., Schurk,R., Ritter
 E., Kohn,S., Shin,T., Jackson,Y., Cardenas,M., McCann,R.,
 Waterston,R. and Wilson,R.
 The WashU-NCI Mouse EST Project 1999

JOURNAL Unpublished (1999)
 COMMENT Contact: Maria M/WashU-NCI Mouse EST Project 1999
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: mouseest@wustl.edu

This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.lnl.gov) for further information.
 MGI:652847
 This clone was previously sequenced on the 5' end only, this new
 data is from the 3' end
 High quality sequence stop: 51.

Location/Qualifiers
 1. 57
 /organism="Mus musculus"
 /strain="C57BL/6"
 /db_xref="taxon:10090"
 /clone="IMAGE:1227255"
 /sex="females"
 /tissue.type="whole skin"
 /dev.stage="11 weeks old"
 /lab_host="SOLR (Xanaycin resistant)"
 /note="Organ: skin; Vector: pBluescript SK-; Site_1: EcoRI
 /site_2: XhoI; Cloned unidirectionally. Primer: Oligo
 dt. Whole skin from 11 week old C57BL/6 female mice.
 Average insert size: 1.0 kb; Uni-ZAP XR Vector; ~5'
 adaptor sequence: 5' GAATTCGACAGAG 3' ~3' adaptor
 sequence: 5' CTCGAGCTTTTCTTTTCTTTTCTTTT 3' "

BASE COUNT 17 a 9 c 12 g 19 t
 ORIGIN

Query Match 55.9%; Score 16.2; DB 9; Length 57;
 Best Local Similarity 37.9%; Pred. No. 4.3e+04;

Email: cgapds-remail.nin.gov
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R. Emmert-Buck, M.D., Ph.D.
CDNA Library Preparation: M. Bento Soares, Ph.D.
CDNA Library Arrayed by: Greg Lennon, Ph.D.

DNA Sequencing by: Washington University Genome Sequencing Center
 Clone distribution: NCI-CGAP clone distribution information can be
 found through the I.M.A.G.E. Consortium/LINL at:
www.bio.linn.gov/biopr/image/image.html
 Insert Length: 1423 Std Error: 0.00

Seq primer: -40up from gibco
 High quality sequence stop: 57.

Location/Qualifiers

FEATURES

source

1. 90

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone="IMAGE:2296130"

/clone_lib="NCI-CGAP_Kid11"

/lab_host="DH10B"

/note="Organ: Kidney; Vector: pT7T3D-Pac (Pharmacia) with
 a modified polylinker; Site_1: Not I; Site_2: Eco RI;
 Plasmid DNA from the normalized library NCI-CGAP_Kid1 was
 prepared, and ss circles were made in vitro. Following HAP
 purification, this DNA was used as tracer in a subtractive
 hybridization reaction. The driver was PCR-amplified cDNAs
 from a pool of 5,000 clones made from the same library
 (cloneids 1322376-1323911, 1456007-1456775, and
 1500552-1502855). Subtraction by Bento Soares and M.
 Fatima Bonaldo."

BASE COUNT

21 a 17 c 25 g 27 t

ORIGIN

Query Match

Best Local Similarity 37.5%; Pred. No. 4.7e+04; Length 90;
 Matches 9; Conservative 10; Mismatches 5; Indels 0; Gaps 0;

QY 6 uucuuuuuuaagccuagggcu 29

Db 4 TTCTTTTGTGGACCTAGGGGAT 27

RESULT 7

AZ923281

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

BASE COUNT

27 a 20 c 16 g 33 t

ORIGIN

4908.gf20g16.sl Saccharomyces cariocanus UFRJ 50791 Saccharomyces
 cariocanus genomic clone 4908.gf20g16.sl, DNA sequence.
 AZ923281
 AZ923281.1 GI:13494179
 GSS.
 Saccharomyces cariocanus.
 Saccharomyces cariocanus.
 Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
 Saccharomycetales; Saccharomycetaceae; Saccharomyces.
 1 (bases 1 to 96)
 Clifton, P.F., Hillier, L.M., Fulton, L., Graves, T., Miner, T., Gish
 W.R., Waterston, R.H. and Johnston, M.
 Surveying Saccharomyces genomes to identify functional elements by
 comparative DNA sequence analysis
 Unpublished (2001)
 Contact: Johnston M
 Department of Genetics
 Washington University Medical School
 Box 8232, 4566 Scott Ave., St. Louis, MO 63110, USA
 Tel: 314 362 2735
 Fax: 314 362 7855
 Email: mj@genetics.wustl.edu
 Class: random plasmid subclone.
 Location/Qualifiers
 1. 96
 /organism="Saccharomyces cariocanus"
 /strain="UFRJ 50791"
 /db_xref="taxon:114526"
 /clone="4908.gf20g16.sl"
 /clone_lib="Saccharomyces cariocanus UFRJ 50791"
 /note="Random genomic sequence"

FEATURES

source

1. 96

/organism="Saccharomyces cariocanus"

/strain="UFRJ 50791"

/db_xref="taxon:114526"

/clone="4908.gf20g16.sl"

/clone_lib="Saccharomyces cariocanus UFRJ 50791"

/note="Random genomic sequence"

BASE COUNT

27 a 20 c 16 g 33 t

ORIGIN

Query Match 55.2%; Score 16; DB 12; Length 96;
 Best Local Similarity 41.7%; Pred. No. 4.7e+04;
 Matches 10; Conservative 9; Mismatches 5; Indels 0; Gaps 0;

QY 6 uucuuuuuuaagccuagggcu 29

Db 73 TTTTTCCTTAACCAAGGGGCT 96

RESULT 8

TA123H02P/c

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

BASE COUNT

29 a 8 c 9 g 20 t

ORIGIN

66 bp DNA linear GSS 13-DEC-2000
 T. Brucei sheared genomic DNA clone 123h02, forward sequence,
 genomic survey sequence.
 AL463084
 AL463084.1 GI:11833690
 GSS.
 Trypanosoma brucei.
 Trypanosoma brucei
 Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae;
 Trypanosoma.
 1 (bases 1 to 66)
 Hall, N., Bowman, S., Leonard, N.J., Doggett, J., Atkin, R.,
 Chillingworth, C., Ormond, D., Harris, B., El-Sayed, N., Hou, L.,
 Melville, S.E., Rajandream, M.A. and Barrell, B.G.
 Direct Submission
 Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing
 project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton,
 Cambridge CB10 1SA, E-mail: barrellesanger.ac.uk and
 nh@sanger.ac.uk
 Constructed at the Institute for Genomic Research (TIGR),
 Rockville, MD. Genomic DNA isolated from a cloned population of
 Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared
 to give a tight size distribution (4 kb). The v + i method used for the library construction is
 described in detail in Smith, H. and Venter, J.C. (Making small
 insert libraries for whole genome shotgun sequencing projects. In
 Genome Sequencing: A Practical Approach, eds. M. Vaudin and B.
 Barrell, Oxford University Press, 1999).
 Email: nelsayed@tigr.org
 Details of T. brucei sequencing at the Sanger Centre are available
 at http://www.sanger.ac.uk/Projects/T_brucei/.

FEATURES

source

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

/clone="123h02"

Location/Qualifiers

1. 66

/organism="Trypanosoma brucei"

/strain="TREU927"

/db_xref="taxon:5691"

REFERENCE
AUTHORS

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 81)
Dunn, P., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausen, A. and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

TITLE

JOURNAL

COMMENT

Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLG, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0264 row: J column: 16
Seq primer: CACACAGCAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 81.

FEATURES

SOURCE

Location/Qualifiers
1..81
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUCG2M0264J16"
/clone_lib="Mouse 10kb plasmid UUCG2M library"
/sex="Female"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g1473214|gb|AF129072.1) a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
ORIGIN

28 a 10 c 33 g 10 t

Query Match

Best Local Similarity 53.1%; Score 15.4; DB 12; Length 81;
Matches 12; Conservative 7; Mismatches 6; Indels 0; Gaps 0;

Qy 5 aaucuuuuuuaagccuagggcu 29

Db 45 ATTCTTCTGCTGCGCTCAGGGGCT 21

RESULT 10

H13996/c

LOCUS H13996 100 bp mRNA linear EST 03-JUL-1995
DEFINITION EST00022 Chromosome 19p12-p13.1 exon Homo sapiens cDNA clone C3-8
5', mRNA sequence.

ACCESSION H13996
VERSION H13996.1 GI:888005

KEYWORDS
SOURCE human.

ORGANISM

Homo sapiens

REFERENCE
AUTHORS

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo. 1 (bases 1 to 100)
Li, O.Y.
Chromosome 19p12-p13.1 exons
Unpublished (1995)

JOURNAL

COMMENT

Human Molecular Genetics
Queen's Medical Centre
Nottingham, NG7 2UH, UK
Tel: 1159249924
Fax: 1159709906
Email: pdzqyl@pdnl.gene.nottingham.ac.uk
Seq primer: SD2 : 5' ARC TCA GTG GTA TTT GNC AGC 3'.

FEATURES

SOURCE

Location/Qualifiers
1..100
/organism="Homo sapiens"
/db_xref="taxon:9606"
/map="19p12-p13.1"
/clone="C3-8"
/clone_lib="Chromosome 19p12-p13.1 exon"
/lab_host="E. coli DH5a"
/note="Vector: PAMP10; Exons were isolated from human chromosome 19p12-p13.1 specific cosmids from Lawrence Livermore National Laboratory using a modification of the method of exon amplification (Proc. Natl. Acad. Sci. USA 88: 4005-4009, 1991). Amplified exons were cloned into PAMP10 by uracil cloning (GIBCOL BRL)."

BASE COUNT
ORIGIN

22 a 35 c 24 g 19 t

Query Match 52.4%; Score 15.2; DB 10; Length 100;
Best Local Similarity 46.4%; Pred. No. 9.2e+04;
Matches 13; Conservative 7; Mismatches 8; Indels 0; Gaps 0;

Qy 2 augauuuuuuuaagccuagggcu 29

Db 96 AAGATGATTTTGGTTAGGCTCAGGGGCT 69

RESULT 11

BE545968

LOCUS BE545968 89 bp mRNA linear EST 09-AUG-2000
DEFINITION 601069329F2 NIH-MGC_12 Homo sapiens cDNA clone IMAGE:3455694 5',
mRNA sequence.

ACCESSION BE545968
VERSION BE545968.1 GI:9774613

KEYWORDS

SOURCE

ORGANISM

human.
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE

AUTHORS

1 (bases 1 to 89)
NIH-MGC http://mhc.nci.nih.gov/.
National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)

JOURNAL

COMMENT

Contact: Robert Strausberg, Ph.D.
Email: cgabbs@mail.nih.gov
Tissue Procurement: ATCC
cDNA Library Preparation: Life Technologies, Inc.
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Plate: U1AM8442 row: 1 column: 07
High quality sequence stop: 89.

FEATURES

SOURCE

Location/Qualifiers
1..89
/organism="Homo sapiens"
/db_xref="taxon:9606"

```

/clone="IMAGE:3455694"
/clone_lib="NIH_MGC_12"
/tissue_type="cervical carcinoma cell line"
/lab_host="DH10B"
/notes="Organ: cervix; Vector: pCMV-Sport6; Site_1: NotI;
Site_2: SalI; Cloned unidirectionally. Primer: Oligo dt.
Average insert size 1.4 kb. Library prepared by Life
Technologies."
BASE COUNT      41 a      14 c      12 g      22 t
ORIGIN
Query Match      51.7%; Score 15; DB 10; Length 89;
Best Local Similarity 39.1%; Pred. No. 1.1e+05;
Matches 9; Conservative 9; Mismatches 5; Indels 0; Gaps 0;
QY 1 uauuauuuuuuuuagccca 23
DB 21 TATGACACTTTTCTAGGCTCTA 43

```

```

RESULT 12
LOCUS      25 bp      DNA      linear      GSS 27-APR-2001
DEFINITION 2M0277P20R Mouse 10kb plasmid UUGC2M library Mus musculus genomic
ACCESSION  A2993079
VERSION     A2993079
KEYWORDS   A2993079.1 GI:13864306
SOURCE     GSS.
ORGANISM   house mouse.
            Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1 (bases 1 to 25)
AUTHORS    Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamli,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Rellily
            M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A.
            and Wright,D., Weiss,R.
            Mouse whole genome scaffolding with paired end reads from 10Kb
            plasmid inserts
            Unpublished (2000)
JOURNAL     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunne@genetics.utah.edu
            Insert Length: 10000 Std Error: 0.00
            Plate: 0277 row: P column: 20
            Seq primer: CACACAGCAACAGCATATGACC
            Class: Plasmid ends
            High quality sequence stop: 25.
FEATURES
            Location/Qualifiers
            1..25
            /organism="Mus musculus"
            /strain="C57BL/6J"
            /db_xref="taxon:10090"
            /clone="UUGC2M0277P20"
            /clone_lib="Mouse 10kb plasmid UUGC2M library"
            /sex="Female"
            /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
            /note="Vector: PMD42ny; Purified genomic DNA from M.
            musculus C57BL/6J (female) was obtained from the Jackson
            Laboratory Mouse DNA Resource
            (http://www.jax.org/resources/documents/dnares/). The DNA
            was hydrodynamically sheared by repeated passage through a
            0.005 inch orifice at constant velocity. The sheared DNA
            was blunt end-repaired with T4 DNA polymerase and T4
            polynucleotide kinase. Adaptor oligonucleotides were
            ligated to the blunt ends in high molar excess. The
            adaptor DNA was purified and size-selected for a 9.5 to

```

```

10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PMD42 (G11473211419b1AF129072.1), a copy-number
inducible derivative of plasmid RL. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor mouse DNA was annealed to
adaptor vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
BASE COUNT      4 a      8 c      6 g      7 t
ORIGIN
Query Match      51.0%; Score 14.8; DB 12; Length 25;
Best Local Similarity 72.2%; Pred. No. 1.6e+05;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 11 uuuuuagcccuaggggc 28
DB 21 TTTGCAAGCCCAAGGGGC 4

```

```

RESULT 13
LOCUS      60 bp      mRNA      linear      EST 20-OCT-2000
DEFINITION 601447803F1 NIH_MGC_65 Homo sapiens cDNA clone IMAGE:3851880 5',
ACCESSION  BE871815
VERSION     BE871815
KEYWORDS   BE871815.1 GI:10320591
SOURCE     EST.
ORGANISM   human.
            Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE   1 (bases 1 to 60)
AUTHORS    NIH-MGC http://mgc.nci.nih.gov/.
            National Institutes of Health, Mammalian Gene Collection (MGC)
            Unpublished (1999)
JOURNAL     Contact: Robert Strausberg, Ph.D.
            Email: cgapbs-r@mail.nih.gov
            Tissue Procurement: ATCC
            cDNA Library Preparation: Life Technologies, Inc.
            DNA Sequencing by: Incyte Genomics, Inc.
            Clone distribution: MGC clone distribution information can be
            found through the I.M.A.G.E. Consortium/LLNL at:
            http://image.llnl.gov
            Plate: L1AM9573 row: e column: 01
            High quality sequence stop: 60.
FEATURES
            Location/Qualifiers
            1..60
            /organism="Homo sapiens"
            /db_xref="taxon:9606"
            /clone="IMAGE:3851880"
            /clone_lib="NIH_MGC_65"
            /tissue_type="adenocarcinoma"
            /lab_host="DH10B (phage-resistant)"
            /note="Organ: colon; Vector: pCMV-Sport6; Site_1: NotI;
            Site_2: SalI; Cloned unidirectionally. Primer: Oligo dt.
            Average insert size 1.8 kb. Library constructed by Life
            Technologies."

```

```

BASE COUNT      16 a      11 c      10 g      23 t
ORIGIN
Query Match      51.0%; Score 14.8; DB 10; Length 60;
Best Local Similarity 38.9%; Pred. No. 1.4e+05;
Matches 7; Conservative 9; Mismatches 2; Indels 0; Gaps 0;
QY 2 uuuuuuuuuuuuuuagc 19
DB 10 ATGATTATTTTCTAAGC 27

```



```

FEATURES
source
    Location/Qualifiers
        1..69
            /organism="Homo sapiens"
            /db_xref="taxon:9606"
            /clone_lib="Melton Normalized Human Islet 4 N4-HIS 1"
            /sex="Both"
            /tissue_type="Islets of Langerhans"
            /dev_stage="Adult"
            /lab_host="DH10B"
            /note="Organ: Pancreas; Vector: pSPORNT1; Site_1: Not 1; Site_2: Sal 1; Starting library constructed using SuperScript Plasmid Library Kit (Life Technologies). cDNA made by oligo-dT priming. Size-selected by column fractionation; average insert size 1.08 kb. Library was amplified once on solid support and plasmid DNA from library was prepared. The library DNA was normalized by method #4 from Bonaldo, Lennon, and Soares 1996 Genome Research 6:791-806; 0.5 microgram single-stranded library plasmid DNA was mixed with 5 micrograms PCR product representing library inserts and hybridized to an EcoT of 20. Single-stranded (unhybridized) plasmids were isolated by hydroxyapatite chromatography and used to make this library."
BASE COUNT
8 a 19 g 32 t
ORIGIN

```

	Query Match	51.0%;	Score 14.8;	DB 10;	Length 69;
	Best Local Similarity	30.8%;	Pred. No. 1.4e+05;		
	Matches	8:	Conservative	11:	Mismatches 7; Indels 0; Gaps 0;
OY	1 uaugauucuuuuuguuaagcccaaggg	26			
	: : : : : :				
	: : : : : :				
Db	8 TTTTTTTTTTTTCGCGCCCTAGGG	33			
RESULT 15					
TAI85E0IP/c					
LOCUS	TAI85E0IP	72 bp	DNA	linear	GSS 13-DEC-2000

DEFINITION	T. brucei sheared genomic DNA clone 185e01, forward sequence, genomic survey sequence.
ACCESSION	AL474065
VERSION	AL474065.1
KEYWORDS	GI:11840836
SOURCE	GSS.
ORGANISM	Trypanosoma brucei.
	Trypanosoma brucei
	Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae;
REFERENCE	Trypanosoma.
AUTHORS	1 (bases 1 to 72) Hall, N., Bowman, S., Lennard, N.J., Doggett, J., Atkin, R., Chillingworth, C., Ormond, D., Harris, B., El-Sayed, N., Hou, L., Melville, S.E., Rajandream, M.A. and Barrell, B.G.
TITLE	Direct Submission
JOURNAL	Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and nls@sanger.ac.uk
COMMENT	Constructed at the Institute for Genomic Research (TIGR), Rockville, MD. Genomic DNA isolated from a cloned population of Trypanosoma brucei (TR90927/4 Gutat 10.1) was mechanically sheared to give a tight size distribution (4 kb). The v + i method used for the library construction is described in detail in Smith, H. and Venter, J.C. (making small insert libraries for whole genome shotgun sequencing projects. Genome Sequencing: A Practical Approach, eds. M. Vaudin and B. Barrell, Oxford University Press, 1999). Email: nelsayed@tigr.org Details of T. brucei sequencing at the Sanger Centre are available at http://www.sanger.ac.uk/Projects/T_brucei/ .

```

FEATURES
SOURCE
    Location/Qualifiers
      ..72
      /organism="Trypanosoma brucei"
      /strain="TREU937"
      /db_xref="taxon:5691"
      /clone="185e01"
BASE COUNT      14 a       16 c       25 g       17 t
ORIGIN

Query Match          51.0%; Score 14.8; DB 12; Length 72;
Best Local Similarity 61.1%; Pred. No. 1.4e+05;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0

QY      12 uuuuaagcccuagggggu 29
        ::|||||:|||||:
Db       66 TTCTAAGCCATFAGGGGCT 49

Search completed: September 13, 2002, 12:36:31
Job time: 9962 sec
```


GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2002, 09:54:15 : Search time 63.83 seconds
(without alignments)
111.599 Million cell updates/sec

Title: US-09-310-844C-24

Perfect score: 29

Sequence: 1 unaugauuuuuuuuagccuaggggcu 29

Scoring table: IDENTITY_NUC

Gapop 10.0, Gapext 1.0

Searched: 383533 seqs, 122816752 residues

Total number of hits satisfying chosen parameters: 613726

Minimum DB seq length: 0

Maximum DB seq length: 100

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued_Patents_NA.*

1: /cgn2_6/ptodata/1/ina/5A_COMB.seq.*

2: /cgn2_6/ptodata/1/ina/5B_COMB.seq.*

3: /cgn2_6/ptodata/1/ina/6A_COMB.seq.*

4: /cgn2_6/ptodata/1/ina/6B_COMB.seq.*

5: /cgn2_6/ptodata/1/ina/PTCUS_COMB.seq.*

6: /cgn2_6/ptodata/1/ina/backfillseq1.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Match	Query length	DB ID	Description
1	15.2	52.4	25	4	US-08-943-731-336
2	15.2	52.4	33	1	Sequence 336, App
3	15.2	52.4	90	1	Sequence 5, Appl1
4	14.8	51.0	35	6	Sequence 10, Appl
5	14.8	51.0	5422260-12		Patent No. 5422260
6	14.8	48.3	37	1	Sequence 1, Appl1
7	14.8	48.3	37	1	Sequence 55, Appl
8	14.8	48.3	37	1	Sequence 55, Appl
9	14.8	48.3	37	1	Sequence 55, Appl
10	14.8	48.3	37	1	Sequence 55, Appl
11	14.8	48.3	37	1	Sequence 55, Appl
12	14.8	48.3	37	1	Sequence 55, Appl
13	14.8	48.3	37	1	Sequence 55, Appl
14	14.8	48.3	37	1	Sequence 55, Appl
15	14.8	48.3	37	1	Sequence 55, Appl
16	14.8	48.3	37	1	Sequence 55, Appl
17	14.8	48.3	37	1	Sequence 55, Appl
18	14.8	48.3	37	1	Sequence 55, Appl
19	14.8	48.3	37	1	Sequence 55, Appl
20	14.8	48.3	37	1	Sequence 55, Appl
21	14.8	48.3	37	1	Sequence 55, Appl
22	14.8	48.3	37	1	Sequence 55, Appl
23	14.8	48.3	37	1	Sequence 55, Appl
24	14.8	48.3	37	1	Sequence 55, Appl
25	14.8	48.3	37	1	Sequence 55, Appl
26	14.8	48.3	37	1	Sequence 55, Appl
27	14.8	48.3	37	1	Sequence 55, Appl

28	13.2	45.5	36	2	US-08-882-083-7	Sequence 7, Appl1
29	13.2	45.5	36	2	US-08-558-107-7	Sequence 7, Appl1
30	13.2	45.5	36	3	US-09-243-539-7	Sequence 7, Appl1
31	13.2	45.5	87	4	US-09-364-539-128	Sequence 128, App
32	13	44.8	22	1	US-08-647-584-118	Sequence 46, Appl
33	13	44.8	53	2	US-08-486-969-46	Sequence 10, Appl
34	13	44.8	53	4	US-08-687-865A-10	Sequence 10, Appl
35	13	44.8	53	4	US-09-043-711-10	Sequence 11, Appl
36	13	44.8	55	2	US-08-687-865A-11	Sequence 11, Appl
37	13	44.8	55	4	US-09-043-711-11	Sequence 11, Appl
38	13	44.8	57	1	US-08-192-300-14	Sequence 319, App
39	13	44.8	67	4	US-09-275-850-319	Sequence 12, Appl
40	13	44.8	70	4	US-09-364-539-128	Sequence 40, Appl
41	13	44.8	72	1	US-08-009-265-41	Sequence 40, Appl
42	13	44.8	78	5	PCT-US96-09448-40	Sequence 11, Appl
43	13	44.8	97	1	US-08-210-222-11	Sequence 6, Appl1
44	13	44.8	24	1	US-08-508-778A-6	
45	12.8	44.1				

ALIGNMENTS

RESULT 1
US-08-943-731-336/C
Sequence 336, Application US/08943731
Patent No. 6265157
GENERAL INFORMATION:
APPLICANT: PROCKOP, DARWIN J.
APPLICANT: SPOTILIA, LORETTA D.
APPLICANT: DELTAS, CONSTANTINOS D.
APPLICANT: SEREDA, LARISA
APPLICANT: LARSON, ANDREA W.
APPLICANT: PACK, MICHAEL
APPLICANT: COLIGE, ALAIN
APPLICANT: EARLY, JAMES
APPLICANT: KORRO, JARMO
APPLICANT: ALA-KORRO, LEENA, et al.
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DETECTING
TITLE OF INVENTION: ALTERED TYPE I OR TYPE IX COLLAGEN GENE SEQUENCES
NUMBER OF SEQUENCES: 666
CORRESPONDENCE ADDRESS:
ADDRESSEE: PANITCH SCHWARZE JACOBS & NADEL, P.C.
STREET: ONE COMMERCE SQUARE, 2005 MARKET STREET, 22ND
STREET: FLR.
CITY: PHILADELPHIA
STATE: PA
COUNTRY: USA
ZIP: 19103-7086
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/943,731
FILING DATE: 03-OCT-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/212,322
FILING DATE: 14-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/803,628
FILING DATE: 03-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: DOYLE LEARY P.H.D., KATHRYN
REGISTRATION NUMBER: 36,317
REFERENCE/DOCKET NUMBER: 9598-27
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-567-2991
TELEFAX: 831-494
TELEX: 831-494
INFORMATION FOR SEQ ID NO: 336:

FILING DATE: 02-DEC-1988; 09-DEC-1986

APPLICATION NUMBER: 939,658
FILING DATE: 09-DEC-1986
APPLICATION NUMBER: 932,767
FILING DATE: 18-NOV-1986
APPLICATION NUMBER: 868,410
FILING DATE: 29-MAY-1986
SEQ ID NO: 12
LENGTH: 35
5422260-12

Query Match 51.0%; Score 14.8; DB 6; Length 35;
Best Local Similarity 42.3%; Pred. No. 2.3e+02;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

OY 4 gaucuuuuuuaagccuaggggcu 29
Db 35 GTTTCCTTTGAAAGCTTTGGGGCT 10

RESULT 5
US-09-440-001-1/C
Sequence 1, Application US/09440001
Patent No. 6174696
GENERAL INFORMATION:
APPLICANT: Seman, Leo J.
TITLE OF INVENTION: A METHOD FOR THE DETERMINATION OF HOMOCYSTEINE
FILE REFERENCE: 09/440,001
CURRENT APPLICATION NUMBER: US/09/440,001
CURRENT FILING DATE: 1999-11-12
PRIOR APPLICATION NUMBER: 60/108,099
PRIOR FILING DATE: 1998-11-12
NUMBER OF SEQ ID NOS: 6
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 1
LENGTH: 36
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence:
US-09-440-001-1

Query Match 51.0%; Score 14.8; DB 4; Length 36;
Best Local Similarity 38.5%; Pred. No. 2.3e+02;
Matches 10; Conservative 9; Mismatches 7; Indels 0; Gaps 0;

OY 1 uauuuuuuuuuaagccuaggg 26
Db 33 TATCAAGCTTTTGTCCGCATATGG 8

RESULT 6
US-08-049-264C-55
Sequence 55, Application US/08049264C
Patent No. 5518901
GENERAL INFORMATION:
APPLICANT: Murtagh, James J.
TITLE OF INVENTION: METHODS FOR NUCLEIC ACID DETECTION,
NUMBER OF SEQUENCES: 75
CORRESPONDENCE ADDRESS:
ADDRESSEE: NEEDLE & ROSENBERG, P.C.
STREET: Suite 1200, The Candler Bldg., 127
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30303
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/049,264C
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Pertyman, David G.
REGISTRATION NUMBER: 33,438
REFERENCE/DOCKET NUMBER: 1313.001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404) 688-0770
TELEFAX: (404) 688-9880
INFORMATION FOR SEQ ID NO: 55:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-049-264C-55

Query Match 48.3%; Score 14; DB 1; Length 37;
Best Local Similarity 40.9%; Pred. No. 5.4e+02;
Matches 9; Conservative 8; Mismatches 5; Indels 0; Gaps 0;

OY 6 uucuuuuuuaagccuaggg 27
Db 8 TTTTCTTTTAAACCCGGGGG 29

RESULT 7
US-08-476-562-55
Sequence 55, Application US/08476562
Patent No. 5688669
GENERAL INFORMATION:
APPLICANT: Murtagh, James J.
TITLE OF INVENTION: METHODS FOR NUCLEIC ACID DETECTION,
NUMBER OF SEQUENCES: 75
CORRESPONDENCE ADDRESS:
ADDRESSEE: NEEDLE & ROSENBERG, P.C.
STREET: Suite 1200, The Candler Bldg., 127
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30303
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/476,562
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/049,264
FILING DATE: April 19, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Pertyman, David G.
REGISTRATION NUMBER: 33,438
REFERENCE/DOCKET NUMBER: 1313.004
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404) 688-0770
TELEFAX: (404) 688-9880
INFORMATION FOR SEQ ID NO: 55:
SEQUENCE CHARACTERISTICS:
LENGTH: 37 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

Query Match 48.3%; Score 14; DB 1; Length 44;
Best Local Similarity 40.9%; Pred. No. 5.6e+02;
Matches 9; Conservative 8; Mismatches 5; Indels 0; Gaps 0;

Oy 6 uuuuuuuuagccuaggg 27
Db 42 TTTTAAACCCGGGGG 21

RESULT 11

US-08-476-562-54/C
Sequence 54, Application US/08476562
Patent No. 5688669

GENERAL INFORMATION:

APPLICANT: Murtagh, James J.

TITLE OF INVENTION: METHODS FOR NUCLEIC ACID DETECTION,
NUMBER OF SEQUENCES: 75

CORRESPONDENCE ADDRESS:

ADDRESSEE: NEEDLE & ROSENBERG, P.C.

STREET: Suite 1200, The Candler Bldg., 127

CITY: Atlanta

STATE: Georgia

COUNTRY: USA

ZIP: 30303

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: IBM PC compatible

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/476,562

FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/049,264

FILING DATE: April 19, 1993

ATTORNEY/AGENT INFORMATION:

NAME: Perryman, David G.

REGISTRATION NUMBER: 33,438

REFERENCE/DOCKET NUMBER: 1313,004

TELECOMMUNICATION INFORMATION:

TELEPHONE: (404) 688-0770

TELEFAX: (404) 688-9880

INFORMATION FOR SEQ ID NO: 54:

SEQUENCE CHARACTERISTICS:

LENGTH: 44 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

US-08-476-562-54

Query Match 48.3%; Score 14; DB 1; Length 44;
Best Local Similarity 40.9%; Pred. No. 5.6e+02;
Matches 9; Conservative 8; Mismatches 5; Indels 0; Gaps 0;

Oy 6 uuuuuuuuagccuaggg 27
Db 42 TTTTAAACCCGGGGG 21

RESULT 12

US-08-479-723A-54/C
Sequence 54, Application US/08479723A
Patent No. 5744306

GENERAL INFORMATION:

APPLICANT: Murtagh, James J.

TITLE OF INVENTION: METHODS FOR NUCLEIC ACID DETECTION,
NUMBER OF SEQUENCES: 87

CORRESPONDENCE ADDRESS:

ADDRESSEE: NEEDLE & ROSENBERG, P.C.

STREET: Suite 1200, The Candler Bldg., 127

CITY: Atlanta

STATE: Georgia

COUNTRY: USA

ZIP: 30303

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: IBM PC compatible

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/479,723A

FILING DATE: 07-JUN-1995

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Perryman, David G.

REGISTRATION NUMBER: 33,438

REFERENCE/DOCKET NUMBER: 05010,0061

TELECOMMUNICATION INFORMATION:

TELEPHONE: (404) 688-0770

TELEFAX: (404) 688-9880

INFORMATION FOR SEQ ID NO: 54:

SEQUENCE CHARACTERISTICS:

LENGTH: 44 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: oligonucleotide

US-08-479-723A-54

Query Match 48.3%; Score 14; DB 1; Length 44;
Best Local Similarity 40.9%; Pred. No. 5.6e+02;
Matches 9; Conservative 8; Mismatches 5; Indels 0; Gaps 0;

Oy 6 uuuuuuuuagccuaggg 27
Db 42 TTTTAAACCCGGGGG 21

RESULT 13

PCT-US94-04310-54/C
Sequence 54, Application PC/TUS9404310

GENERAL INFORMATION:

APPLICANT:

TITLE OF INVENTION: METHODS FOR NUCLEIC ACID DETECTION,
NUMBER OF SEQUENCES: 74

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: IBM PC compatible

SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US94/04310

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/049,264

FILING DATE: 19-APR-1993

INFORMATION FOR SEQ ID NO: 54:

SEQUENCE CHARACTERISTICS:

LENGTH: 44 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

PCT-US94-04310-54

Query Match 48.3%; Score 14; DB 5; Length 44;
Best Local Similarity 40.9%; Pred. No. 5.6e+02;

Matches	9;	Conservative	8;	Mismatches	5;	Indels	0;	Gaps	0;
QY	6	ucuuuuuuagcccuaggg	27						
		::::: :							
Db	42	TTTTTTTTTAACCGGGG	21						

RESULT 14
 US-09-440-001-3/C
 Sequence 3, Application US/09440001
 Patent No. 6174696
 GENERAL INFORMATION:
 APPLICANT: Seman, Leo J.
 TITLE OF INVENTION: A METHOD FOR THE DETERMINATION OF HOMOCYSTEINE
 FILE REFERENCE: 09/440,001
 CURRENT APPLICATION NUMBER: US/09/440,001
 CURRENT FILING DATE: 1999-11-12
 PRIOR APPLICATION NUMBER: 60/108,099
 PRIOR FILING DATE: 1998-11-12
 NUMBER OF SEQ ID NOS: 6
 SOFTWARE: PatentIn Ver. 2.0
 SEQ ID NO 3
 LENGTH: 36
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Description of Artificial Sequence:
 US-09-440-001-3
 OTHER INFORMATION: Oligonucleotide primer

	Query Match	47.6%	Score 13.8;	DB 4	Length 36;
	Best Local Similarity	40.0%	Pred. NO. 6.7e+02;		
	Matches	10; Conservative	8; Mismatches	7;	Indels 0; Gaps 0.
OY	1 uaugauucuuuuuguuaagcccuagg	25			
	: : : : : : : : : : :				
Dd	28 TATCAAGCTTTTGTGCCCGCCGGG	4			

US-08-343-443B-39
: Sequence 39, Application US/08343443B
: Patent No. 5968734
: GENERAL INFORMATION:
: APPLICANT: Aurias, Alain
: APPLICANT: Delattre, Olivier
: APPLICANT: Desmazes, Chantal
: APPLICANT: Melot, Thomas
: APPLICANT: Peter, Martine
: APPLICANT: Ploogastel, Beatrice
: APPLICANT: Thomas, Gilles
: APPLICANT: Zucman, Jessica
: TITLE OF INVENTION: NUCLEIC ACID CORRESPONDING TO A GENE OF
: TITLE OF INVENTION: CHROMOSOME 22 INVOLVED IN RECURRENT CHROMOSOMAL
: TITLE OF INVENTION: TRANSLATIONS ASSOCIATED WITH THE DEVELOPMENT OF CANCEROUS
: TITLE OF INVENTION: TUMORS, AND NUCLEIC ACIDS OF FUSION RESULTING FROM SAID
: TITLE OF INVENTION: TRANSLATIONS
: NUMBER OF SEQUENCES: 129
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Weiser & Associates
: STREET: 230 South Fifteenth Street
: CITY: Philadelphia
: STATE: PA
: COUNTRY: USA
: ZIP: 19102
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: AEDIT 1.0 DOS text editor
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/343,443B

```

1          CILING DATE: 18-NOV-1994
2          CLASSIFICATION: 514
3          PRIOR APPLICATION DATA:
4          APPLICATION NUMBER: PCT/FR93/004944
5          FILING DATE: 19-MAY-1993
6          PRIOR APPLICATION DATA:
7          APPLICATION NUMBER: FR 92/06123
8          FILING DATE: 20-MAY-1992
9          ATTORNEY/AGENT INFORMATION:
10         NAME: Weiser, Gerard J.
11         REGISTRATION NUMBER: 19,763
12         REFERENCE/DOCKET NUMBER: 989,6121P
13         TELECOMMUNICATION INFORMATION:
14         TELEPHONE: 215-875-8383
15         TELEFAX: 215-875-8394
16         INFORMATION FOR SEQ ID NO: 39:
17         SEQUENCE CHARACTERISTICS:
18         LENGTH: 44 base pairs
19         TYPE: nucleic acid
20         STRANDEDNESS: double
21         TOPOLOGY: linear
22
23 US-08-343-443B-39

```

Query Match	46.9%	Score 13.6	DB 2	Length 44
Best Local Similarity	35.7%	Pred. No. 8.6e+02		
Matches	10	Conservative	9	Mismatches 9
				Indels 0
				Gaps 0
QY	1	naugaauuuuuuuuuaagccccaaggggc	28	
	:	: : : : : : : : : : : : : : : : :		
DB	14	tggtttctctgtgtgagccagagagcc	41	

Search completed: September 13, 2002, 12:37:52
Job time: 9817 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2002, 11:58:05 ; Search time 280.51 Seconds
(without alignments)
177.500 Million cell updates/sec

Title: US-09-310-844C-24

Perfect score: 1 uagauuuuuuuuagccuaggggcu 29

Sequence: IDENTITY_NDC
Gapop 10.0 , Gapext 1.0

Scoring table: 1736436 segs, 858457221 residues

Total number of hits satisfying chosen parameters: 2046006

Minimum DB seq length: 0
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_032802.*
1: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.*
2: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.*
3: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.*
4: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.*
5: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.*
6: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.*
7: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.*
8: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.*
9: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.*
10: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.*
11: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.*
12: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.*
13: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.*
14: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.*
15: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.*
16: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.*
17: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.*
18: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.*
19: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.*
20: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.*
21: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.*
22: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA2001.DAT.*
23: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.*
24: /SIDS1/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match length	DB ID	Description
1	29	100.0	29 21 AAA70828	Molecular interact
2	29	100.0	42 21 AAA71123	Molecular interact
3	29	100.0	42 21 AAA71131	Molecular interact
4	28	96.6	45 21 AAA70824	Molecular interact
5	28	96.6	46 21 AAA71087	Molecular interact
6	28	96.6	46 21 AAA71096	Molecular interact
7	28	96.6	46 21 AAA71099	Molecular interact
8	28	96.6	46 21 AAA71100	Molecular interact
9	28	96.6	46 21 AAA71104	Molecular interact

10	25.8	89.0	42 21 AAA71113	Molecular interact
11	25.8	89.0	42 21 AAA71118	Molecular interact
12	25.8	89.0	42 21 AAA71126	Molecular interact
13	24.8	85.5	46 21 AAA71085	Molecular interact
14	24.8	85.5	46 21 AAA71103	Molecular interact
15	23.8	82.1	42 21 AAA71114	Molecular interact
16	23.8	82.1	42 21 AAA71119	Molecular interact
17	23.8	82.1	42 21 AAA71127	Molecular interact
18	23.8	82.1	46 21 AAA71094	Molecular interact
19	23.8	82.1	46 21 AAA71110	Molecular interact
20	23.2	80.0	29 21 AAA70829	Molecular interact
21	23.2	80.0	29 21 AAA70830	Molecular interact
22	23.2	80.0	42 21 AAA71115	Molecular interact
23	23.2	80.0	42 21 AAA71116	Molecular interact
24	23.2	80.0	42 21 AAA71120	Molecular interact
25	23.2	80.0	42 21 AAA71121	Molecular interact
26	23.2	80.0	42 21 AAA71128	Molecular interact
27	23.2	80.0	42 21 AAA71129	Molecular interact
28	22.6	77.9	42 21 AAA71124	Molecular interact
29	22.6	77.9	42 21 AAA71132	Molecular interact
30	22.2	76.6	45 21 AAA70825	Molecular interact
31	22.2	76.6	45 21 AAA70826	Molecular interact
32	22.2	76.6	46 21 AAA71088	Molecular interact
33	22.2	76.6	46 21 AAA71089	Molecular interact
34	22.2	76.6	46 21 AAA71090	Molecular interact
35	22.2	76.6	46 21 AAA71105	Molecular interact
36	22.2	76.6	46 21 AAA71106	Molecular interact
37	22.2	76.6	46 21 AAA71107	Molecular interact
38	21.6	74.5	46 21 AAA71093	Molecular interact
39	21.6	74.5	46 21 AAA71095	Molecular interact
40	21.6	74.5	46 21 AAA71109	Molecular interact
41	21.6	74.5	46 21 AAA71111	Molecular interact
42	19.4	66.9	46 21 AAA71084	Molecular interact
43	19.4	66.9	46 21 AAA71098	Molecular interact
44	19.4	66.9	46 21 AAA71102	Molecular interact
45	18.4	63.4	42 21 AAA71117	Molecular interact

ALIGNMENTS

RESULT 1
AAA70828 standard; RNA; 29 BP.
XX
AC AAA70828;
XX
XX 27-APR-2001 (first entry)
XX
DE Molecular interaction site RNA #28.
XX
KM Modulator; identification; molecular interaction; virtual library; ss.
XX
OS Homo sapiens
XX
PN R0958947-A2.
XX
PD 18-NOV-1999
XX
PE 12-MAY-1999; 99WO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Grifey R, Crooke ST, Sampath R, Swayze E, Mohan V;
XX
XX Hotstadler S, McNeil J;
XX
XX WPI: 2000-086439/07.
XX
XX Identifying compounds which modulate activity of target biomolecules,
XX used to provide compounds which can be used as pharmacological,
XX

PT	agricultural and industrial compounds -
XX	
PS	Claim 235; Page 235; 405pp; English.

This invention describes a novel method for identifying compounds which modulate the activity of a target biomolecule. The method uses 3-dimensional representations of the biomolecule and a library of compounds and comprises (a) identifying at least one molecular interaction site of the target RNA; (b) generating in silico a virtual library of compounds predicted or calculated to interact with the molecular interaction site; and (c) comparing 3-dimensional (3-D) representations of the target RNA with members of the virtual library of compounds to generate a hierarchy of the compounds ranked in accordance with their respective ability to form physical interactions with the molecular interaction site. The method also describes (1) RNA comprising a joined sequence of at least 24 nucleotides but not more than 70 nucleotides and having secondary structure defined by: (a) 3 nucleotides forming a first side of a first double stranded (ds) region; (b) 2 nucleotides forming a first side of an internal loop region; (c) 4 nucleotides forming a first side of a second ds region; (d) 4 or 5 nucleotides forming an end loop region; (e) 4 nucleotides forming a second side of the second ds region; (f) 4 nucleotides forming a second side of the internal loop region; and (g) 3 nucleotides forming a second side of the first ds region; (2) a purified and isolated RNA fragment comprising the human sequence UUAACACUAAUUCUGUUAACGAAAAAC (II). The methods and products can be used for identifying agents which modulate the activity of biomolecules, particularly RNA. Such agents can be used as pharmaceutical, agricultural or industrial compounds.

Sequence 29 BP; 5 A; 5 C; 7 G; 12 U; 0 other;

Query Match	100.0%	Score 29;	DB 21;	Length 29;
Best Local Similarity	100.0%	Pred. No. 0.00092;		
Matches 29;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0

[illegible]

RESULT	2
AAA71123	
ID	AAA71123 standard; DNA; 42 BP.

DT 27-APR-2001 (first entry)

DE Molecular interaction site DNA #129.

Modulator; identification; molecular interaction; virtual library; ss.

.....
OS
Unidentified.

PN / W09958947-A2

18-NOV-1999

12-MAY-1999: 99WO-US10361.

12-MAY-1998: 98HIS-0076404

PR 12-MAY-1998; 9805-0085092.
XX

PA (ISIS-) ISIS PHARM INC.
YY

PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V, ~~ref: 1~~

[illegible]

XX

PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds
XX
PS Example 7; Figure 125; 405pp; English.

This invention describes a novel method for identifying compounds which modulate the activity of a target biomolecule. The method uses 3-dimensional representations of the biomolecule and a library of compounds and comprises (a) identifying at least one molecular interaction site of the target RNA; (b) generating in silico a virtual library of compounds predicted or calculated to interact with the molecular interaction site; and (c) comparing 3-dimensional (3-D) representations of the target RNA with members of the virtual library of compounds to generate a hierarchy of the compounds ranked in accordance with their respective ability to form physical interactions with the molecular interaction site. The method also describes (1) RNA comprising a joined sequence of at least 24 nucleotides but not more than 70 nucleotides and having secondary structure defined by: (a) 3 nucleotides forming a first side of a first double stranded (ds) region; (b) 2 nucleotides forming a first side of an internal loop region; (c) 4 nucleotides forming a first side of a second ds region; (d) 4 or 5 nucleotides forming an end loop region; (e) 4 nucleotides forming a second side of the second ds region; (f) 4 nucleotides forming a second side of the internal loop region; and (g) 3 nucleotides forming a second side of the first ds region; (2) a purified and isolated RNA fragment comprising the human sequence UUUUACUUAUUCAGUUGUACGAAAAUUC (II). The methods and products can be used for identifying agents which modulate the activity of biomolecules, particularly RNA. Such agents can be used as pharmaceutical, agricultural or industrial compounds.

Sequence 42 BP; 9 A; 6 C; 9 G; 18 T; 0 other;

Query Match	100.0%;	Score 29;	DB 21;	length 42;
Best Local Similarity	58.6%;	Pred. No. 0.00096;		
Matches 17;	Conservative 12;	Mismatches 0;	Indels 0;	Gaps 0;

OY		1	naugauucuuuuuguaaagcccuagggcgu	29
	:	:	: :: :: :	
Dd	4	tatgattcctttgttaagccctaaggsgct	32	

RESULT	3
AAA71131	
ID	AAA71131 standard; RNA; 42 BP.

DT 27-APR-2001 (first entry)

DE Molecular interaction site RNA #200

KW ~~Modulator~~; identification; molecular interaction; virtual library; ss.

OS ~~Unidentified~~

PN / W09958947-A2

18-NOV-1999

12-MAY-1999 99WO-US10361

12-MAY-1998: 98TTS-0076404

PR 12-MAY-1998; 9805-0085092.
XX

PA (ISIS-) ISIS PHARM, INC.

PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

XX

XX

PT used to provide compounds which can be used as pharmacological,

PT Identifying compounds which modulate activity of target biomolecules
PT used to provide compounds which can be used as pharmacological,

PT Identifying compounds which modulate activity of target biomolecules
PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
PS
PS Example 7, Figure 121: 405pp: English.
XX
XX This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACUUAUUCAGUUUACAGAAAUUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
XX Sequence 46 BP; 11 A; 7 C; 9 G; 19 T; 0 other;

Query Match	96.6%	Score 28	DB 21	Length 46
Best Local Similarity	60.7%	Pred No. 0.0028		
Matches 17; Conservative	11	Mismatches 0	Indels 0	Gaps 0

OY 1 naugaaucuuuuuguuaagcccuagggc 28
 :|||::|:::|||||:||||
Db 19 tatgatcttctttgttaagccctagggc 46

RESULT	6
AAA71096	
ID	AAA71096 standard; DNA; 46 BP

AC	AAA71096;
XX	
DT	27-APR-2001 (first entry)

DE Molecular interaction site DNA #119.

M Modulator; identification; molecular interaction; virtual library; ss
 XX
 OS Unidentified.

W09958947-A2.

PD 18-NOV-1999

AF 12-MAY-1999;
YY

PR	12-MAY-1998;	98US-0076404.
DP	12-MAY-1998.	98US-0085092

XX (TSTS-) TSTS PHARM INC

XX
PI Ecker DJ. ~~Crifley R.~~ Crook

PL HOIStale S, Mcneil J;
XX

DR WEL; 2000-086439/01.
XX

PT used to provide compounds which can be used as pharmacological,

XX agricultural and industrial compounds -
PS
XX Example 7, Figure 121, 405pp: English.
XX
XX This invention describes a novel method for identifying compounds which
XX modulate the activity of a target biomolecule. The method uses
XX 3-dimensional representations of the biomolecule and a library of
XX compounds and comprises (a) identifying at least one molecular
XX compound and (b) generating in silico a virtual
XX library of compounds predicted or calculated to interact with the
XX molecular interaction site; and (c) comparing 3-dimensional (3-D)
XX representations of the target RNA with members of the virtual library of
XX compounds to generate a hierarchy of the compounds ranked in accordance
XX with their respective ability to form physical interactions with the
XX molecular interaction site. The method also describes (1) RNA comprising
XX a joined sequence of at least 24 nucleotides but not more than 70
XX nucleotides and having secondary structure defined by: (a) 3 nucleotides
XX forming a first side of a first double stranded (ds) region; (b) 2
XX nucleotides forming a first side of an internal loop region; (c) 4
XX nucleotides forming a first side of a second ds region; (d) 4 or 5
XX nucleotides forming an end loop region; (e) 4 nucleotides forming a
XX second side of the second ds region; (f) 4 nucleotides forming a second
XX side of the internal loop region; and (g) 3 nucleotides forming a second
XX side of the first ds region; (2) a purified and isolated RNA fragment
XX comprising the human sequence UUUACACUUAUUCUUAUUCACGAAUAUC (11). The
XX methods and products can be used for identifying agents which modulate
XX the activity of biomolecules, particularly RNA. Such agents can be used
XX as pharmaceutical, agricultural or industrial compounds.
XX
XX Sequence 46 BP, 11 A; 7 C; 9 G; 19 T; 0 other;
XX

Query Match	96.6%	Score 28:	DB 21:	Length 46:
Best Local Similarity	60.7%	Pred. No. 0.0028:		
Best Match	17:	Conservative	0:	Indels 0:
				Gaps 0:

QY 1 naugaauucuuuuuguaagcccuaggcgc 28
 :|::||::||::||::||::||::||
Db 19 tatgatctcttltgtaagccctaggcgc 46

RESULT	7
AAA71099	
ID	AAA71099 standard; DNA; 46 BP

AC	AAA71099;
XX	
DT	27-APR-2001 (first entry)

DE Molecular interaction site DNA #122.

KW	Modulator; identification; molecular interaction; virtual library; ss.
XX	
08	Unidentified.

PN W09958947-A2.

PD 18-NOV-1999.

PF 12-MAY-1999;
VY

PR	12-MAY-1998;	98US-0076404.
PR	12-MAY-1998;	98US-0085092

XX (TSTS-) TSTS PHARM INC

XX	Ecker D.J.	Griffey R.	Crook
PI			

PI Hotstadler S, McNeill J;
XX

DR WP1; 2000-08439/0/.

PT identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,
PT

[illegible]

PT used to provide compounds which can be used as pharmacological,

[illegible]

PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
XX Example 7; Figure 122; 405bp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACUAUUCUAGUUUACGAAAAUUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 46 BP; 11 A; 7 C; 9 G; 19 U; 0 other;

Query Match 96.6%; Score 28; DB 21; Length 46;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 uaugauuuuuuuuuaagccuaggggc 28
DB 19 uaugauuuuuuuuuaagccuaggggc 46

RESULT 10
AA71113
ID AAA71113 standard; RNA; 42 BP.

AC AAA71113;

DT 27-APR-2001 (first entry)

DE Molecular interaction site RNA #189.

KW Modulator identification; molecular interaction; virtual library; ss.

OS Unidentified.

PN W09958947-R2.

PD 18-NOV-1999.

PR 12-MAY-1999; 99MO-US10361.

PR 12-MAY-1998; 98US-0076404.

PR 12-MAY-1998; 98US-0085092.

PA (ISIS-) ISIS PHARM INC.

PI Becker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

DR Hofstadler S, McNeil J;

XX WPI; 2000-086439/07.

PT Identifying compounds which modulate activity of target biomolecules,
used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
XX Example 7; Figure 122; 405bp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACUAUUCUAGUUUACGAAAAUUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 42 BP; 12 A; 7 C; 6 G; 17 U; 0 other;

Query Match 89.0%; Score 25.8; DB 21; Length 42;
Best Local Similarity 93.1%; Pred. No. 0.027;
Matches 27; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1 uaugauuuuuuuuuaagccuaggggc 29
DB 4 uaugauuuuuuuuuaagccuaggggc 32

RESULT 11
AA71118
ID AAA71118 standard; DNA; 42 BP.

AC AAA71118;

DT 27-APR-2001 (first entry)

DE Molecular interaction site DNA #124.

KW Modulator identification; molecular interaction; virtual library; ss.

OS Unidentified.

PN W09958947-R2.

PD 18-NOV-1999.

PR 12-MAY-1999; 99MO-US10361.

PR 12-MAY-1998; 98US-0076404.

PR 12-MAY-1998; 98US-0085092.

PA (ISIS-) ISIS PHARM INC.

PI Becker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

DR Hofstadler S, McNeil J;

XX WPI; 2000-086439/07.

PT Identifying compounds which modulate activity of target biomolecules,
used to provide compounds which can be used as pharmacological,

PT Agricultural and industrial compounds -

XX Example 7; Figure 125; 405bp; English.

CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACAUAUCUGUUUACGAAAAUUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

XX Sequence 42 BP; 12 A; 7 C; 6 G; 17 T; 0 other;

Query Match 89.0%; Score 25.8; DB 21; Length 42;

Best Local Similarity 55.2%; Pred. No. 0.027; Mismatches 16; Conservative 11; Indels 0; Gaps 0;

QY 1 uauaguuuuuuuuuagagccuagggcu 29
Db 4 taagatcttcttgtaagcctaagcgct 32

RESULT 12

AAA71126 standard; RNA; 42 BP.

XX AAA71126;

XX 27-APR-2001 (first entry)

XX Molecular interaction site RNA #195.

XX Modulator identification; molecular interaction; virtual library; ss.

XX Unidentified

XX MO9958947-A2.

XX 18-NOV-1999.

XX 12-MAY-1999; 99WO-0510361.

XX 12-MAY-1998; 98US-0076404.

XX 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

XX Hofstadler S, McNeil J;

XX WPI; 2000-086439/07.

XX Identifying compounds which modulate activity of target biomolecules,

XX used to provide compounds which can be used as pharmacological,

PT Agricultural and industrial compounds -

XX Example 7; Figure 126; 405bp; English.

CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACAUAUCUGUUUACGAAAAUUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.

XX Sequence 42 BP; 12 A; 7 C; 6 G; 17 U; 0 other;

Query Match 89.0%; Score 25.8; DB 21; Length 42;

Best Local Similarity 93.1%; Pred. No. 0.027; Mismatches 27; Conservative 0; Indels 0; Gaps 0;

QY 1 uauaguuuuuuuuuagagccuagggcu 29
Db 4 uauaguuuuuuuuuagagccuagggcu 32

RESULT 13

AAA71085 standard; DNA; 46 BP.

XX AAA71085;

XX 27-APR-2001 (first entry)

XX Molecular interaction site DNA #108.

XX Modulator identification; molecular interaction; virtual library; ss.

XX Unidentified

XX MO9958947-A2.

XX 18-NOV-1999.

XX 12-MAY-1999; 99WO-0510361.

XX 12-MAY-1998; 98US-0076404.

XX 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

XX Hofstadler S, McNeil J;

XX WPI; 2000-086439/07.

XX Identifying compounds which modulate activity of target biomolecules,

XX used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
PS Example 7; Figure 121; 405bp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACAUUACUUCUACACAAAAC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
SQ Sequence 46 BP; 12 A; 7 C; 9 G; 18 T; 0 other;

Query Match 85.5%; Score 24.8; DB 21; Length 46;
Best Local Similarity 57.1%; Pred. No. 0.076;
Matches 16; Conservative 10; Mismatches 2; Indels 0; Gaps 0;

OY 1 uauaauuuuuuuuagccuagggc 28
DB 19 taagatcttcttgaagccctagggc 46

RESULT 14
ID AAA71103 standard; RNA; 46 BP.
XX
AC AAA71103;

DT 27-APR-2001 (first entry)

XX Molecular interaction site RNA #179.

XX Modulator; identification; molecular interaction; virtual library; ss.

OS Unidentified.

XX WO9558947-A2.

XX 18-NOV-1999.

XX 12-MAY-1999; 99MO-US10361

XX 12-MAY-1998; 98US-0076404.

XX 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

XX Hotsfader S, McNeil J;

XX WPI; 2000-086439/07.

PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
PS Example 7; Figure 122; 405bp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACAUUACUUCUACACAAAAC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
SQ Sequence 46 BP; 12 A; 7 C; 9 G; 18 U; 0 other;

Query Match 85.5%; Score 24.8; DB 21; Length 46;
Best Local Similarity 92.9%; Pred. No. 0.076;
Matches 26; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1 uauaauuuuuuuuagccuagggc 28
DB 19 uauaauuuuuuuuagccuagggc 46

RESULT 15
ID AAA71114 standard; RNA; 42 BP.
XX
AC AAA71114;

DT 27-APR-2001 (first entry)

XX Molecular interaction site RNA #190.

XX Modulator; identification; molecular interaction; virtual library; ss.

OS Unidentified.

XX WO9558947-A2.

XX 18-NOV-1999.

XX 12-MAY-1999; 99MO-US10361.

XX 12-MAY-1998; 98US-0076404.

XX 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

XX Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

XX Hotsfader S, McNeil J;

XX WPI; 2000-086439/07.

PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,

PF agricultural and industrial compounds -
 XX
 PS Example 7; Figure 122; 405bp; English.
 XX

CC This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming a first side of a second ds region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACAUAUAGUUGUUACAGAAAUAUC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX
 SQ Sequence 42 BP; 11 A; 8 C; 7 G; 16 U; 0 other;

Query Match 82.1%; Score 23.8; DB 21; Length 42;
 Best Local Similarity 92.6%; Pred. No. 0.21;
 Matches 25; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1 uauagauucuuuuuuaagcccuagggg 27
 || |||||
 Db 4 uaagaauucuuuuuuaagcccuagggc 30

Search completed: September 13, 2002, 13:23:15
 Job time: 5110 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2002, 11:56:05 ; Search time 2058.64 Seconds
(Without alignments)
294.791 Million cell updates/sec

Title: US-09-310-844C-24
Sequence: 1 uauaauuuuuuuaagccuaggggcu 29

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 1797656 seqs, 10463268293 residues
Total number of hits satisfying chosen parameters: 843946

Minimum DB seq length: 0
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : GenEmbl:*
1: gb_ba:*
2: gb_hlg:*
3: gb_in:*
4: gb_cm:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_un:*
14: gb_vi:*
15: em_ba:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vi:*
30: em_hlg_hum:*
31: em_hlg_inv:*
32: em_hlg_other:*
33: em_hlg_inv:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Match Length	ID	Description
1	16	AF144669	Patella vulgata antennapedia-like homeodomain protein HB3 gene.
2	15.2	AR020509	Patella vulgata antennapedia-like homeodomain protein HB3 gene.
3	15.2	136126	Novel G pro
4	15.2	E49126	Novel G pro
5	15.7	E50836	Novel G pro
6	15.7	D50836	Novel G pro
7	14.8	108597	Sequence 12
8	14.8	AR142180	Sequence 12
9	14.6	AR142180	Sequence 12
10	14.6	AF328713	Sequence 12
11	14.6	50.3	Sequence 12
12	14.6	50.3	Sequence 12
13	14.4	49.7	Sequence 12
14	14.4	49.7	Sequence 12
15	14.2	49.0	Sequence 12
16	14.2	49.0	Sequence 12
17	14.2	49.0	Sequence 12
18	14.2	49.0	Sequence 12
19	14.2	49.0	Sequence 12
20	14.2	49.0	Sequence 12
21	14.2	49.0	Sequence 12
22	14.2	49.0	Sequence 12
23	14.2	49.0	Sequence 12
24	14.2	49.0	Sequence 12
25	14.2	49.0	Sequence 12
26	14.2	49.0	Sequence 12
27	14.2	49.0	Sequence 12
28	14.2	49.0	Sequence 12
29	14.2	49.0	Sequence 12
30	14.2	49.0	Sequence 12
31	14.2	49.0	Sequence 12
32	14.2	49.0	Sequence 12
33	14.2	49.0	Sequence 12
34	14.2	49.0	Sequence 12
35	14.2	49.0	Sequence 12
36	14.2	49.0	Sequence 12
37	14.2	49.0	Sequence 12
38	14.2	49.0	Sequence 12
39	14.2	49.0	Sequence 12
40	14.2	49.0	Sequence 12
41	14.2	49.0	Sequence 12
42	14.2	49.0	Sequence 12
43	13.8	47.6	Sequence 12
44	13.8	47.6	Sequence 12
45	13.8	47.6	Sequence 12

C	1	16	55.2	82	3	AF144669
C	2	15.2	52.4	33	6	AR020509
C	3	15.2	52.4	90	6	I36126
C	4	15.2	51.7	40	6	E49126
C	5	15	51.7	40	6	E50836
C	6	15	51.7	87	3	D50836
C	7	14.8	51.0	35	6	108597
C	8	14.8	51.0	36	6	AR142180
C	9	14.6	50.3	51	6	AR142180
C	10	14.6	50.3	51	10	AF328713
C	11	14.6	50.3	72	9	S63972
C	12	14.6	50.3	72	1	ECOPRYD2
C	13	14.4	49.7	25	6	AX042583
C	14	14.4	49.7	25	6	AX043280
C	15	14.2	49.0	35	6	AX298174
C	16	14.2	49.0	45	6	104390
C	17	14.2	49.0	56	6	AX247478
C	18	14.2	49.0	100	4	AY045354
C	19	14.2	49.0	100	4	AY045355
C	20	14.2	49.0	100	4	AY045356
C	21	14.2	49.0	100	4	AY045357
C	22	14.2	49.0	100	4	AY045358
C	23	14.2	49.0	100	4	AY045359
C	24	14.2	49.0	100	4	AY045360
C	25	14.2	49.0	100	4	AY045361
C	26	14.2	49.0	100	4	AY045362
C	27	14.2	49.0	100	4	AY045363
C	28	14.2	49.0	100	5	AF174501
C	29	14.2	49.0	100	5	AF174506
C	30	14.2	48.3	30	6	AX113961
C	31	14	48.3	30	6	AX113963
C	32	14	48.3	37	6	AR003420
C	33	14	48.3	37	6	I21209
C	34	14	48.3	37	6	I74476
C	35	14	48.3	44	6	AR003419
C	36	14	48.3	44	6	I21208
C	37	14	48.3	44	6	I74475
C	38	14	48.3	78	14	AF362846
C	39	14	48.3	78	14	AF362847
C	40	14	48.3	78	14	AF362849
C	41	14	48.3	100	9	HOMO4011
C	42	14	48.3	100	9	HOMO5011
C	43	13.8	47.6	35	6	AR142182
C	44	13.8	47.6	42	6	AX017119
C	45	13.8	47.6	42	6	AX017120

ALIGNMENTS

RESULT	LOCUS	DEFINITION	ACCESSION	VERSION	KEYWORDS	ORGANISM	REFERENCE	TITLE	JOURNAL
1	AF144669/c	Patella vulgata antennapedia-like homeodomain protein HB3 gene.	AF144669	partial cds.	AF144669.1 GI:5690267	common limpet. Patella vulgata Eukaryota; Metazoa; Mollusca; Gastropoda; Archaeogastropoda; Patelloidea; Patelidae; Patella.	de Rosa, R., Grenier, J.K., Andreeva, T., Cook, C.E., Adoutte, A., Akam, M., Carroll, S.B. and Balavaine, G. Hox genes in brachiopods and trilobites and protostome evolution Nature 399 (6738), 772-776 (1999)	99318125	PUBMED 10391241
2	(bases 1 to 82)	de Rosa, R., Grenier, J.K., Andreeva, T., Cook, C.E., Adoutte, A., Akam, M., Carroll, S.B. and Balavaine, G. Hox genes in brachiopods and trilobites and protostome evolution Nature 399 (6738), 772-776 (1999)	2	(bases 1 to 82)	Submitted (21-APR-1999)	Centre de Genetique Moleculaire, Avenue de			

FEATURES	La Terrasse, Gif-sur-Yvette 91199, France
source	Location/Qualifiers
	1..82
	/organism="Patella vulgata"
	/db_xref="taxon:6465"
mrna	<1..>82
	/product="antennapedia-like homeodomain protein HB3"
cds	<1..>82
	/codon_start=2
	/product="antennapedia-like homeodomain protein HB3"
	/protein_id="AAD4708.1"
	/db_xref="gi:5690268"
	/translation="HNNRYLRRRRIRVAAHMLGTERQIKI"
BASE COUNT	34 a 16 c 17 g 15 t
ORIGIN	

Query Match	55.2%;	Score 16;	DB 3;	Length 82;
Best Local Similarity	45.8%;	Pred No. 7.3e+03;		
Matches 11; Conservative	8;	Mismatches 5;	Indels 0;	Gaps 0;

1 uagauucuuuuuguagcccuag 24
 :|: :|:: :|:||||| |
76 TATTGTCTTCTGTAAGCCCGAG 53

RESULT					
AR020509/2					
LOCUS	AR020509	33 bp	DNA	linear	PAT 05-DEC-1998
DEFINITION	Sequence	5 from patent US 5768171.			
ACCESSION	AR020509				
VERSION	AR020509.1	GI:3975124			
KEYWORDS					
SOURCE	Unknown.				

REFERENCE	1 (bases 1 to 33)
AUTHORS	Smeltzer, M.S.
TITLE	Use of cna, fnba, fnbb, and hlb, gene probes for the strain-specific identification of <i>Staphylococcus aureus</i>
JOURNAL	Patent: US 5789171-A 5 04-AUG-1998
FEATURES	Location/Qualifiers
source	1..33

```
BASE COUNT      12 a      8 c      7 g      6 t
ORIGIN
```

Query Match	52.4%	Score 15.2	DB 6	Length 33
Best Local Similarity	39.3%	Pred. NO. 1,8e-04		
Matches 11, Conservative	9	Mismatches 8	Indels 0	Gaps 0
2 augauuuuuuuuagaagccuagggcu 29				
32 ATGATTGTTTAAATTTCCCGGGCT 5				
db				

RESULT	3		
LOCUS	136126	90 bp	DNA
DEFINITION	Sequence 10 from patent US 5604131.		linear
ACCESSION	136126		
VERSION	136126.1	GI:2087350	
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	Unclassified.		
AUTHORS	1 (bases 1 to 90)		
TITLE	Wadsworth,S., Snyder,B., Reddy,V.B. and Wei,C.		
JOURNAL	CNA-genomic DNA hybrid sequence encoding APT770 containing a		
FEATURES	genomic DNA insert of the KI and OX-2 regions		
	Patent: US 5604131-A 10 18-FEB-1997;		
	Location/Qualifiers		

```

source      1. .90
            /organism="unknown"
BASE COUNT  18 a      23 c      20 g      29 t
ORIGIN

```

	Query Match	52.4%	Score 15.2;	DB 6;	Length 90;
	Best Local Similarity	35.0%;	Pred. No..1.7e+04;		
Matches	7; Conservative	10; Mismatches	3; Indels	0; Gaps	0;
Qy	3 ugaauucuuuuuuuaagcccu	22			
	: ::: :: :: :				
Dd	56 tgaatccttttcttgacgctct	75			

QY 3 ugaucuuuuuugaagcccu 22
:||:|:|:|:|:|:|:|:|:|:
Db 56 TGATTCITTTTGTGTCTCT 75

RESULT	4
E49126/c	
LOCUS	40 bp DNA linear
DEFINITION	Novel G protein-coupled receptor protein.
ACCESSION	E49126
VERSION	E49126.1 GI:18629263
KEYWORDS	JP 2001029083-A/4.
SOURCE	Homo sapiens.
ORGANISM	Homo sapiens
PAT	31-JAN-2002

REFERENCE	1 (bases 1 to 40)
AUTHORS	Takasaka, A., Matsumoto, M., Sugimoto, T., Kamahara, M. and Saito, S.
TITLE	Novel G protein-coupled receptor protein
JOURNAL	Patent: JP 2001029083-A 4 06-FEB-2001; YAMANOUCHI PHARMACEUT CO LTD
COMMENT	OS Homo sapiens (human)

PF 23-JUL-1999 JP 1999209918
PR
PI ATSUSHI TAKASAKI, MITSUYUKI MATSUMOTO, TAKASHI SUGIMOTO, PI

Key	Location/Qualifiers
EH	1..40
FT	/organism='Homo sapiens (human)'

FEATURES	Location/Qualifiers
SOURCE	1. .40 /organism="Homo sapiens" /db_xref="taxon:9606"
BASE COUNT	10 a 8 c 4 g 18 t
ORIGIN	

Query Match	51.7%	Score 15:	DB 6:	Length 40:
Best Local Similarity	47.8%	Pred. No.	2.2e+04:	
Matches 11; Conservative	7;	Mismatches	5;	Indels 0; Gaps 0;

```
QY      1  uaugauucuuuuuguuaagccca 23
      :|:|:|:|:|:|:|:|:|:|
Db     35  TATGATTCTTATAGAAGTCCAA 13
```

RESULT	5	40 bp	DNA	linear	PAT 31-JAN-2002
LOCUS	E50836/c				
DEFINITION	Novel G protein-coupled receptor.				
ACCESSION	E50836				
VERSION	E50836.1	GI:18633541			
KEYWORDS	JP 2001054389-A/4.				
SOURCE	Homo sapiens.				

ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
 1 (bases 1 to 40)
 Takasaki, A., Matsumoto, M., Sugimoto, T., Kanahara, M. and Salto, S.
 Novel G protein-coupled receptor
 Patent: JP 2001054389-A 4 27-FEB-2001;
 YAMANOUCHI PHARMACEUT CO LTD
 COMMENT OS Homo sapiens (human)
 PN JP 2001054389-A/4
 PD 27-FEB-2001
 PE 17-AUG-1999 JP 1999230777
 PR ATSUHI TAKASAKI, MITSUYUKI MATSUMOTO, TAKASHI SUGIMOTO, PI
 MASAZUMI KANAHARA,
 PI SATOSHI SATO
 PC C12N5/09, C07K14/705, C07K16/28, C12N1/15, C12N1/19, C12N1/21, PC
 C12N5/10,
 PC C12P21/02, G01N33/15, G01N33/50//C12P21/08, (C12P21/02, C12R1:91),
 PC C12N5/00,
 PC C12N5/00
 CC
 FH key Location/Qualifiers
 FT source 1.40
 /organism="Homo sapiens (human)"
 Location/Qualifiers
 1..40
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 BASE COUNT 10 a 8 c 4 g 18 t
 ORIGIN

Query Match 51.7%; Score 15; DB 6; Length 40;
 Best Local Similarity 47.8%; Pred. No. 2.2e+04;
 Matches 11; Conservative 7; Mismatches 5; Indels 0; Gaps 0;

QY 1 uauuauuuuuuuuagaccucca 23
 :|||:|||||
 Db 35 TATGATCTTATAGAAAGTCCAA 13

RESULT 6
 DDIDKD/c 87 bp DNA linear INV 27-APR-1993
 LOCUS DDIDKD
 DEFINITION D.discoideum protein kinase 4 gene, partial cds.
 ACCESSION M59747
 VERSION M59747.1 GI:167723
 KEYWORDS protein kinase 4.
 SOURCE Dictyostelium discoideum (strain AX-3) DNA.
 ORGANISM Dictyostelium discoideum
 Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
 1 (bases 1 to 87)
 Haribabu, B. and Dotti, R.P.
 Identification of a protein kinase multigene family of
 Dictyostelium discoideum: Molecular cloning and expression of a
 cDNA encoding a developmentally regulated protein kinase
 Proc. Natl. Acad. Sci. U.S.A. 88, 1115-1119 (1991)
 91142122
 Location/Qualifiers
 1..87
 /organism="Dictyostelium discoideum"
 /strain="AX-3"
 /db_xref="taxon:44689"
 <1..>87
 /codon_start=1
 /product="protein kinase 4"
 /protein_id="AA33189.1"
 /db_xref="GI:167724"
 /translation="NLLIDYGHKLDPGFAKRTENTKSMC"
 BASE COUNT 36 a 12 c 14 g 25 t
 ORIGIN

Query Match 51.7%; Score 15; DB 3; Length 87;
 Best Local Similarity 39.1%; Pred. No. 2.1e+04;
 Matches 9; Conservative 9; Mismatches 5; Indels 0; Gaps 0;

QY 1 uauuauuuuuuuuagaccucca 23
 :|||:|||||
 Db 66 TGTGATCTTTTGGCAATCCAA 44

RESULT 7
 108597/c 35 bp
 LOCUS 108597
 DEFINITION Sequence 12 from Patent WO 8707144.
 ACCESSION 108597
 VERSION 108597.1 GI:588701
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 35)
 AUTHORS Kauffman, R.J., Piltman, D.D. and Toole, J.J.J.
 TITLE NOVEL PROCOAGULANT PROTEINS
 JOURNAL Patent: WO 8707144-A 12 03-DEC-1987;
 FEATURES Location/Qualifiers
 source 1..35
 /organism="unknown"
 BASE COUNT 18 a 8 c 5 g 4 t
 ORIGIN

Query Match 51.0%; Score 14.8; DB 6; Length 35;
 Best Local Similarity 42.3%; Pred. No. 2.8e+04;
 Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 gauuauuuuuuuuagaccuccu 29
 :|||:|||||
 Db 35 GTTTCCTTTTGAAGCTTTGGGGCT 10

RESULT 8
 ARI42180/c 36 bp DNA linear PAT 08-AUG-2001
 LOCUS ARI42180
 DEFINITION Sequence 1 from patent US 6174696.
 ACCESSION ARI42180
 VERSION ARI42180.1 GI:15102480
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 36)
 AUTHORS Seman, L.
 TITLE Method for the determination of homocysteine
 JOURNAL Patent: US 6174696-A 1 16-JAN-2001;
 FEATURES Location/Qualifiers
 source 1..36
 /organism="unknown"
 BASE COUNT 12 a 7 c 9 g 8 t
 ORIGIN

Query Match 51.0%; Score 14.8; DB 6; Length 36;
 Best Local Similarity 38.5%; Pred. No. 2.8e+04;
 Matches 10; Conservative 9; Mismatches 7; Indels 0; Gaps 0;

QY 1 uauuauuuuuuuuagaccuccu 26
 :|||:|||||
 Db 33 TATCAAGCTTTTGTCCGCATATGG 8

RESULT 9
 AX115517 51 bp DNA linear PAT 11-MAY-2001
 LOCUS AX115517

JOURNAL
Mol. Gen. Genet. 194, 179-187 (1984)


```

/organism="synthetic construct"
/db_xref="taxon:32630"
/note="DQAI heterozygote primer sequence"

```

Search completed: September 13, 2002, 13:18:15
Job time: 4930 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2002, 13:23:15 : Search time 280.51 Seconds
(without alignments)
177.500 Million cell updates/sec

Title: US-09-310-844c-25

Perfect score: 29

Sequence: 1 aagaauuuuuuuuagaccccaaggcgcu 29

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 2046006

Minimum DB seq length: 0
Maximum DB seq length: 100

Post-processing: Minimum Match 08
Maximum Match 100%

Listing first 45 summaries

Database :

N.Geneseq_032802.*
1: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*
2: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*
3: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*
4: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*
5: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*
6: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*
7: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*
8: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*
9: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
10: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*
11: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*
12: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*
13: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*
14: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*
15: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*
16: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*
17: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*
18: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*
19: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*
20: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*
21: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*
22: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*
23: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*
24: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	29	100.0	29	21	AAA70829
2	29	100.0	29	21	AAA70830
3	29	100.0	42	21	AAA71115
4	29	100.0	42	21	AAA71116
5	29	100.0	42	21	AAA71120
6	29	100.0	42	21	AAA71121
7	29	100.0	42	21	AAA71128
8	29	100.0	42	21	AAA71129
9	29	96.6	45	21	AAA70825

10	28	96.6	45	21	AAA70826	Molecular interact
11	28	96.6	46	21	AAA71088	Molecular interact
12	28	96.6	46	21	AAA71089	Molecular interact
13	28	96.6	46	21	AAA71090	Molecular interact
14	28	96.6	46	21	AAA71105	Molecular interact
15	28	96.6	46	21	AAA71106	Molecular interact
16	28	96.6	46	21	AAA71107	Molecular interact
17	24.8	85.5	42	21	AAA71113	Molecular interact
18	24.8	85.5	42	21	AAA71118	Molecular interact
19	24.8	85.5	42	21	AAA71126	Molecular interact
20	23.8	82.1	46	21	AAA71085	Molecular interact
21	23.8	82.1	46	21	AAA71103	Molecular interact
22	23.2	80.0	42	21	AAA70828	Molecular interact
23	23.2	80.0	42	21	AAA71123	Molecular interact
24	23.2	80.0	42	21	AAA71131	Molecular interact
25	22.2	76.6	45	21	AAA70824	Molecular interact
26	22.2	76.6	46	21	AAA71087	Molecular interact
27	22.2	76.6	46	21	AAA71096	Molecular interact
28	22.2	76.6	46	21	AAA71099	Molecular interact
29	22.2	76.6	46	21	AAA71100	Molecular interact
30	22.2	76.6	46	21	AAA71104	Molecular interact
31	21.2	73.1	42	21	AAA71114	Molecular interact
32	21.2	73.1	42	21	AAA71119	Molecular interact
33	21.2	73.1	42	21	AAA71127	Molecular interact
34	21.2	73.1	46	21	AAA71094	Molecular interact
35	21.2	73.1	46	21	AAA71110	Molecular interact
36	20	69.0	46	21	AAA71084	Molecular interact
37	20	69.0	46	21	AAA71098	Molecular interact
38	19.6	67.6	46	21	AAA71102	Molecular interact
39	19.6	67.6	42	21	AAA71124	Molecular interact
40	19.6	67.6	42	21	AAA71132	Molecular interact
41	18.6	64.1	46	21	AAA71093	Molecular interact
42	18.6	64.1	46	21	AAA71095	Molecular interact
43	18.6	64.1	46	21	AAA71109	Molecular interact
44	18.6	64.1	46	21	AAA71111	Molecular interact
45	18.4	63.4	42	21	AAA71117	Molecular interact

ALIGNMENTS

RESULT 1
ID AAA70829 standard; RNA: 29 BP.
XX
AC AAA70829:
XX
XX 27-APR-2001 (first entry)
DT
DE Molecular interaction site RNA #29.
XX
KW Modulator; identification: molecular interaction: virtual library; ss.
XX
OS Mus sp.
XX
PN W0958947-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999: 99MO-US10361.
XX
PR 12-MAY-1998: 98US-0076404.
PR 12-MAY-1998: 98US-0085092.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Becker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
XX Hofstadler S, McNeill J;
XX WPI: 2000-086439/07.
XX
XX Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
PS Claim 235; Page 235; 405pp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACUAUUCUGUUAACGAAAAUUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 29 BP; 8 A; 6 C; 6 G; 9 U; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 29;
Best Local Similarity 100.0%; Pred. No. 0.00096;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 aaagaauuuuuuuuaagccccaagggu 29
Db 1 aaagaauuuuuuuuaagccccaagggu 29

RESULT 2
ID AAA70830 standard; RNA: 29 BP.
XX
AC AAA70830;
XX
DT 27-APR-2001 (first entry)
XX
DE Molecular interaction site RNA #30.
XX
KM Modulator; Identification: molecular interaction; virtual library; ss.
XX
OS Rattus sp.
XX
PN WO958947-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999; 99MO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
XX
PI Hofstadler S, McNeil J;
XX
DR WPI; 2000-086439/07.
XX
PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
PS Claim 235; Page 235; 405pp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACUAUUCUGUUAACGAAAAUUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 29 BP; 8 A; 6 C; 6 G; 9 U; 0 other;

Query Match 100.0%; Score 29; DB 21; Length 29;
Best Local Similarity 100.0%; Pred. No. 0.00096;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 aaagaauuuuuuuuaagccccaagggu 29
Db 1 aaagaauuuuuuuuaagccccaagggu 29

RESULT 3
ID AAA71115 standard; RNA: 42 BP.
XX
AC AAA71115;
XX
DT 27-APR-2001 (first entry)
XX
DE Molecular interaction site RNA #191.
XX
KM Modulator; Identification: molecular interaction; virtual library; ss.
XX
OS unidentified.
XX
PN WO958947-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999; 99MO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
XX
PI Hofstadler S, McNeil J;
XX
DR WPI; 2000-086439/07.
XX
PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
XX
PS Example 7; Figure 122; 405pp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACUAUACUUAUUCAGAAUAUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
XX
SQ Sequence 42 BP; 13 A; 7 C; 7 G; 15 U; 0 other;
XX
XX
Query Match 100.0%; Score 29; DB 21; Length 42;
Best Local Similarity 100.0%; Pred. No. 0.001;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 aaagaucuuuuuuaagcccaagagcu 29
|||||
Db 4 aaagaucuuuuuuaagcccaagagcu 32
XX
XX
RESULT 4
AA71116
ID AA71116 standard; RNA; 42 BP.
XX
XX AA71116;
AC
XX 27-APR-2001 (first entry)
DT
XX Molecular interaction site RNA #192.
DE
XX Molecular interaction; molecular interaction; virtual library; ss.
KW
XX Unidentified.
OS
XX WO958947-A2.
PN
XX 18-NOV-1999.
PD
XX 12-MAY-1999; 99WO-US10361.
PF
XX 12-MAY-1998; 98US-0076404.
PR
XX 12-MAY-1998; 98US-0085092.
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI Hofstadler S, McNeil J;
XX
XX WPI: 2000-086439/07.
XX
XX Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
XX
PS Example 7; Figure 122; 405pp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACUAUACUUAUUCAGAAUAUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
XX
SQ Sequence 42 BP; 13 A; 7 C; 7 G; 15 U; 0 other;
XX
XX
Query Match 100.0%; Score 29; DB 21; Length 42;
Best Local Similarity 100.0%; Pred. No. 0.001;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 aaagaucuuuuuuaagcccaagagcu 29
|||||
Db 4 aaagaucuuuuuuaagcccaagagcu 32
XX
XX
RESULT 5
AA71120
ID AA71120 standard; DNA; 42 BP.
XX
XX AA71120;
AC
XX 27-APR-2001 (first entry)
DT
XX Molecular interaction site DNA #126.
DE
XX Molecular interaction; molecular interaction; virtual library; ss.
KW
XX Unidentified.
OS
XX WO958947-A2.
PN
XX 18-NOV-1999.
PD
XX 12-MAY-1999; 99WO-US10361.
PF
XX 12-MAY-1998; 98US-0076404.
PR
XX 12-MAY-1998; 98US-0085092.
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI Hofstadler S, McNeil J;
XX
XX WPI: 2000-086439/07.
XX
XX Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
PS Example 7; Figure 126; 405pp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACAUAUCUGUUAACGAAAAAUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 42 BP; 13 A; 7 C; 7 G; 15 U; 0 other;
XX
XX
Query Match 100.0%; Score 29; DB 21; Length 42;
Best Local Similarity 100.0%; Pred. No. 0.001;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 aaagaauuuuuuuuuaagcccaaggcu 29
Db 4 aaagaauuuuuuuuuaagcccaaggcu 32
XX
RESULT 8
AAA71129 standard; RNA; 42 BP.
XX
AC AAA71129;
XX
DT 27-APR-2001 (first entry)
XX
DE Molecular interaction site RNA #198.
XX
KW Modulator; identification; molecular interaction; virtual library; ss.
XX
OS Unidentified.
XX
OS WO958947-A2.
XX
PN 18-NOV-1999.
XX
PD 12-MAY-1999; 99WO-US10361.
XX
PF 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI Hofstadler S, McNeil J;
XX
XX WPI; 2000-086439/07.
PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
PS Example 7; Figure 126; 405pp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACAUAUCUGUUAACGAAAAAUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 42 BP; 13 A; 7 C; 7 G; 15 U; 0 other;
XX
XX
Query Match 100.0%; Score 29; DB 21; Length 42;
Best Local Similarity 100.0%; Pred. No. 0.001;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 aaagaauuuuuuuuuaagcccaaggcu 29
Db 4 aaagaauuuuuuuuuaagcccaaggcu 32
XX
RESULT 9
AAA70825 standard; RNA; 45 BP.
XX
AC AAA70825;
XX
DT 27-APR-2001 (first entry)
XX
DE Molecular interaction site RNA #25.
XX
KW Modulator; identification; molecular interaction; virtual library; ss.
XX
OS Mus sp.
XX
OS WO958947-A2.
XX
PN 18-NOV-1999.
XX
PD 12-MAY-1999; 99WO-US10361.
XX
PF 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
PI Hofstadler S, McNeil J;
XX
XX WPI; 2000-086439/07.
PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
XX
PS Claim 221; Page 232; 405pp; English.
XX
XX This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACACUAUUCUGUUUACACAAAAC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
XX
SQ Sequence 45 BP; 14 A; 7 C; 9 G; 15 U; 0 other;

Query Match 96.6%; Score 28; DB 21; Length 45;
Best Local Similarity 100.0%; Pred. No. 0.0029;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 aagaauuuuuuuuagaccccaagggc 28
|||||
DB 18 aagaauuuuuuuuagaccccaagggc 45

RESULT 10

AAA70826
ID AAA70826 standard; RNA; 45 BP.

AC AAA70826;

DT 27-APR-2001 (first entry)

DE Molecular interaction site RNA #26.

KW Modulator; identification; molecular interaction; virtual library; ss.

OS Rattus sp.

PN W09958947-A2.

PD 18-NOV-1999.

PF 12-MAY-1999; 99W0-US10361.

PR 12-MAY-1998; 98US-0076404.

PR 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

PI Eckey DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

PI Horstader S, McNeil J;

WPI: 2000-086439/07.

PT Identifying compounds which modulate activity of target biomolecules,
used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
XX
PS Claim 222; Page 232; 405pp; English.
XX
XX This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACACUAUUCUGUUUACACAAAAC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
XX
SQ Sequence 45 BP; 14 A; 7 C; 9 G; 15 U; 0 other;

Query Match 96.6%; Score 28; DB 21; Length 45;
Best Local Similarity 100.0%; Pred. No. 0.0029;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 aagaauuuuuuuuagaccccaagggc 28
|||||
DB 18 aagaauuuuuuuuagaccccaagggc 45

RESULT 11

AAA71088
ID AAA71088 standard; DNA; 46 BP.

AC AAA71088;

DT 27-APR-2001 (first entry)

DE Molecular interaction site DNA #111.

KW Modulator; identification; molecular interaction; virtual library; ss.

OS Unidentified.

PN W09958947-A2.

PD 18-NOV-1999.

PF 12-MAY-1999; 99W0-US10361.

PR 12-MAY-1998; 98US-0076404.

PR 12-MAY-1998; 98US-0085092.

XX (ISIS-) ISIS PHARM INC.

PI Eckey DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;

PI Horstader S, McNeil J;

WPI: 2000-086439/07.

PT Identifying compounds which modulate activity of target biomolecules,
used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
PS
PS Example 7: Figure 121: 405pp: English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACAACUAUUCUGUUUACGAAAUUC (II). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
XX Sequence 46 BP: 14 A; 7 C; 9 G; 16 T; 0 other;

	Query Match	Similarity	96.6%	Score 28;	DB 21;	Length 46;
Best Local	Similarity	71.4%	Pred. NO. 0.0029;			
Matches	20;	Conservative	8;	Matches	0;	Indels
						Gaps
QY	1	aaagaauuuuuuuuuaagccccaagc	28			
		: ::: :				
Db	19	aaagattctctttgaaagccccaagc	46			

RESULT	13
AAAT71090	
ID	AAAT71090 standard; DNA: 46 BP.
XX	
AC	AAAT71090;
XX	
DT	27-APR-2001 (first entry)
XX	
DE	Molecular interaction site DNA #113.
XX	
KW	Modulator; identification; molecular interaction; virtual library; ss
XX	
OS	unidentified.
XX	
PN	WC0958947-A2.
XX	
PD	18-NOV-1999.
XX	
PF	12-MAY-1999; 99WO-US10361.
XX	
PR	12-MAY-1998; 98US-0076404.
XX	
PR	12-MAY-1998; 98US-0085092.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	
PI	Ecker DJ, Griffey R, Crooke ST, Sampath R, Swayze E, Mohan V;
XX	
PI	Hotstadler S, McNeil J;
XX	
DR	WPI: 2000-086439/07.
XX	

PT agricultural and industrial compounds -
XX
PS Example 7; Figure 121; 405bp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACUAUUCUAGUUUACGAAAUUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 46 BP; 14 A; 7 C; 9 G; 16 T; 0 other;

Query Match 96.6%; Score 28; DB 21; Length 46;
Best Local Similarity 71.4%; Pred. No. 0.0029;
Matches 20; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

OY 1 aaagaucuuuuuuuagaccaccaaggc 28
|||||:|||||:|||||:|||||
DB 19 aaagattctttgttaagccccaaggc 46

RESULT 14
AAAT71105
ID AAA71105 standard; RNA: 46 BP.
XX
AC AAA71105;

XX 27-APR-2001 (first entry)
XX
DE Molecular interaction site RNA #181.

XX
KM Modulator; identification; molecular interaction; virtual library; ss.

XX OS Unidentified.
XX
PN WO958947-A2.
XX
PD 18-NOV-1999.

XX PF 12-MAY-1999; 99WO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.

XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Grilley R, Crooke ST, Sampath R, Swayze E, Mohan V;
XX
PI Hofstadler S, McNeil J;
XX
DR WPI; 2000-086439/07.
XX
PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
XX
PS Example 7; Figure 122; 405bp; English.
XX
CC This invention describes a novel method for identifying compounds which
CC modulate the activity of a target biomolecule. The method uses
CC 3-dimensional representations of the biomolecule and a library of
CC compounds and comprises (a) identifying at least one molecular
CC interaction site of the target RNA; (b) generating in silico a virtual
CC library of compounds predicted or calculated to interact with the
CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
CC representations of the target RNA with members of the virtual library of
CC compounds to generate a hierarchy of the compounds ranked in accordance
CC with their respective ability to form physical interactions with the
CC molecular interaction site. The method also describes (1) RNA comprising
CC a joined sequence of at least 24 nucleotides but not more than 70
CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
CC forming a first side of a first double stranded (ds) region; (b) 2
CC nucleotides forming a first side of an internal loop region; (c) 4
CC nucleotides forming a first side of a second ds region; (d) 4 or 5
CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
CC second side of the second ds region; (f) 4 nucleotides forming a second
CC side of the internal loop region; and (g) 3 nucleotides forming a second
CC side of the first ds region; (2) a purified and isolated RNA fragment
CC comprising the human sequence UUUACACUAUUCUAGUUUACGAAAUUC (11). The
CC methods and products can be used for identifying agents which modulate
CC the activity of biomolecules, particularly RNA. Such agents can be used
CC as pharmaceutical, agricultural or industrial compounds.
XX
SQ Sequence 46 BP; 14 A; 7 C; 9 G; 16 U; 0 other;

Query Match 96.6%; Score 28; DB 21; Length 46;
Best Local Similarity 100.0%; Pred. No. 0.0029;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 aaagaucuuuuuuuagaccaccaaggc 28
|||||:|||||:|||||:|||||
DB 19 aaagaucuuuuuuuagaccaccaaggc 46

RESULT 15
AAAT71106
ID AAA71106 standard; RNA: 46 BP.
XX
AC AAA71106;

XX 27-APR-2001 (first entry)
XX
DE Molecular interaction site RNA #182.

XX
KM Modulator; identification; molecular interaction; virtual library; ss.

XX OS Unidentified.
XX
PN WO958947-A2.
XX
PD 18-NOV-1999.

XX PF 12-MAY-1999; 99WO-US10361.
XX
PR 12-MAY-1998; 98US-0076404.
XX
PR 12-MAY-1998; 98US-0085092.

XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Ecker DJ, Grilley R, Crooke ST, Sampath R, Swayze E, Mohan V;
XX
PI Hofstadler S, McNeil J;
XX
DR WPI; 2000-086439/07.
XX
PT Identifying compounds which modulate activity of target biomolecules,
PT used to provide compounds which can be used as pharmacological,

PT agricultural and industrial compounds -
 XX
 PS
 XX Example 7; Figure 122; 405pp; English.

CC This invention describes a novel method for identifying compounds which
 CC modulate the activity of a target biomolecule. The method uses
 CC 3-dimensional representations of the biomolecule and a library of
 CC compounds and comprises (a) identifying at least one molecular
 CC interaction site of the target RNA; (b) generating in silico a virtual
 CC library of compounds predicted or calculated to interact with the
 CC molecular interaction site; and (c) comparing 3-dimensional (3-D)
 CC representations of the target RNA with members of the virtual library of
 CC compounds to generate a hierarchy of the compounds ranked in accordance
 CC with their respective ability to form physical interactions with the
 CC molecular interaction site. The method also describes (1) RNA comprising
 CC a joined sequence of at least 24 nucleotides but not more than 70
 CC nucleotides and having secondary structure defined by: (a) 3 nucleotides
 CC forming a first side of a first double stranded (ds) region; (b) 2
 CC nucleotides forming a first side of an internal loop region; (c) 4
 CC nucleotides forming a first side of a second ds region; (d) 4 or 5
 CC nucleotides forming an end loop region; (e) 4 nucleotides forming a
 CC second side of the second ds region; (f) 4 nucleotides forming a second
 CC side of the internal loop region; and (g) 3 nucleotides forming a second
 CC side of the first ds region; (2) a purified and isolated RNA fragment
 CC comprising the human sequence UUUACACAUUACUAGUUUACAGAAAADC (II). The
 CC methods and products can be used for identifying agents which modulate
 CC the activity of biomolecules, particularly RNA. Such agents can be used
 CC as pharmaceutical, agricultural or industrial compounds.
 XX

SQ Sequence 46 BP; 14 A; 7 C; 9 G; 16 U; 0 other;

Query Match 96.6%; Score 28; DB 21; Length 46;
 Best Local Similarity 100.0%; Pred. No. 0.0029;
 Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 aaagaucuuuuuuaagccccaagggc 28
 ||||||||||||||||||||
 DB 19 aaagaucuuuuuuaagccccaagggc 46

Search completed: September 13, 2002, 13:23:15
 Job time: 5110 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2002, 13:18:15 : Search time 2058.64 Seconds
(without alignments) 294.791 Million cell updates/sec

Title: US-09-310-844C-25

Perfect score: 29

Sequence: 1 aaagaucuuuuuuuagagcccaaggagcu 29

Scoring table:

IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1797656 seqs, 10463268293 residues

Total number of hits satisfying chosen parameters: 843946

Minimum DB seq length: 0
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

GenDbml:*
1: gb_da:*
2: gb_htg:*
3: gb_in:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_un:*
14: gb_vl:*
15: em_ba:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vl:*
30: em_htg_hum:*
31: em_htg_inv:*
32: em_htg_other:*
33: em_htgo_inv:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query	Score	Match	Length	DB	ID	Description
------------	-------	-------	-------	--------	----	----	-------------

C	1	16.2	55.9	48	6	AX018731	AX018731 Sequence
C	2	15.4	53.1	73	6	E02131	E02131 Pseudoknot
C	3	15.2	52.4	33	6	AR020509	AR020509 Sequence
C	4	15	51.7	23	23	E09974	E09974 Primer for
C	5	15	51.7	23	23	E10118	E10118 PCR primer
C	6	14.8	51.0	29	6	AR019319	AR019319 Sequence
C	7	14.8	51.0	29	6	AR061847	AR061847 Sequence
C	8	14.8	51.0	29	6	AR014758	AR014758 Sequence
C	9	14.8	51.0	29	6	134733	134733 Sequence 25
C	10	14.8	51.0	29	6	167987	167987 Sequence 25
C	11	14.8	51.0	32	6	AR061867	AR061867 Sequence
C	12	14.8	51.0	80	6	A52215	A52215 Sequence 5
C	13	14.6	50.3	25	6	AX043294	AX043294 Sequence
C	14	14.6	50.3	53	6	AR061021	AR061021 Sequence
C	15	14.6	50.3	87	3	DDIDKD	DDIDKD
C	16	14.4	49.7	25	6	AX043671	AX043671 Sequence
C	17	14.4	49.7	51	6	AX117185	AX117185 Sequence
C	18	14.4	49.7	81	14	AF166557	AF166557 Hepatitis
C	19	14.4	49.7	81	14	AF166559	AF166559 Hepatitis
C	20	14.4	49.7	81	14	AF166560	AF166560 Hepatitis
C	21	14.4	49.7	81	14	AF166561	AF166561 Hepatitis
C	22	14.2	49.0	69	6	AR052906	AR052906 Sequence
C	23	14.2	49.0	69	6	AR054269	AR054269 Sequence
C	24	14.2	49.0	69	6	AR054471	AR054471 Sequence
C	25	14.2	49.0	87	9	HSLASSBIN	X96992 H.sapiens g
C	26	14.2	49.0	100	5	AF174511	AF174511 Bufo mela
C	27	14.2	49.0	100	5	AF174512	AF174512 Bufo mela
C	28	14.2	49.0	100	5	AF174513	AF174513 Bufo mela
C	29	14.2	49.0	100	5	AF174514	AF174514 Bufo mela
C	30	14.2	49.0	100	5	AF174515	AF174515 Bufo mela
C	31	14.2	49.0	100	5	AF174516	AF174516 Bufo mela
C	32	14.2	49.0	100	5	AF174517	AF174517 Bufo mela
C	33	14.2	49.0	100	5	AF174518	AF174518 Bufo mela
C	34	14.2	49.0	100	5	AF174519	AF174519 Bufo mela
C	35	14.2	49.0	100	5	AF174520	AF174520 Bufo mela
C	36	14.2	49.0	100	5	AF174521	AF174521 Bufo mela
C	37	14.2	49.0	100	9	HUM04011	H83920 Human MHC c
C	38	14.2	49.0	100	9	HUM05011	M83921 Human MHC c
C	39	14	48.3	25	6	AX043055	AX043055 Sequence
C	40	14	48.3	41	6	AX316543	AX316543 Sequence
C	41	14	48.3	75	9	AF312283	AF312283 Homo sapi
C	42	14	48.3	100	10	RNU12531	U12531 Rattus norv
C	43	13.8	47.6	27	6	AX249915	AX249915 Sequence
C	44	13.8	47.6	38	9	HSTCRDV21	X69283 H.sapiens m
C	45	13.8	47.6	38	9	HSTCRDV25	X69287 H.sapiens m

ALIGNMENTS

RESULT 1
AX018731/c
LOCUS AX018731 48 bp DNA
DEFINITION Sequence 20 from Patent WO944633.
ACCESSION AX018731
VERSION AX018731.1 GI:10042853
KEYWORDS
SOURCE
ORGANISM
synthetic construct.
artificial sequence.
REFERENCE
1 (bases 1 to 48)
AUTHORS Minke,J.M. and Audonnet,J.C.
TITLE Live recombinant vaccines injected with adjuvant
JOURNAL Patent: WO 944633-A 20 10-SEP-1999.
MINKÉ JULES MAARTEN (FR); MERIAL SAS (FR); AUDONNET JEAN CHRISTOPHE
FRANC (FR)
FEATURES
source
1..48
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Oligonucleotide"

BASE COUNT	17 a	9 c	9 g	13 t
------------	------	-----	-----	------

Query Match	55.9%;	Score 16.2;	DB 6;	Length 48;
Best Local Similarity	44.8%;	Pred. NO. 5.9e+03;		
Matches 13; Conservative	8;	Mismatches 8;	Indels 0;	Gaps 0;

```
QY 1 aaagaucuuuuuuaagccccaagggcu 23
    ||| : ::::| ||| | |||:
Db 37 AAATCTAATTTTGTAGCTTCCGGGCT 9
```

LOCUS	73 bp	RNA	linear	PAT 29-SEP-1997
DEFINITION	Pseudoknot region of 3' non-coding region.			
ACCESSION	E02131			
VERSION	E02131.1	GI:5708465		
KEYWORDS	JP 1989281079-A/3.			
SOURCE	Tobacco mosaic virus.			
ORGANISM				

Viruses; ssRNA positive-strand viruses, no DNA stage: Tobacco etch virus (bases 1 to 73)
 1 (bases 1 to 73)
 AUTHORS Okada, Y. and Takamatsu, N.
 TITLE ATTENUATED STRAIN OF PLANT VIRUS AND PREPARATION THEREOF
 JOURNAL Patent: JP 1989281079-A 3 13-NOV-1989;
 ISSN: 0014-4801

COMMENT	OS	Tobacco mosaic virus
PN	JP 1989281079-A/3	
PD	13-NOV-1989	

PF 09-MAY-1988 JP 1988R110353
PI OKADA YOSHIMI, TAKAMATSU NOBUHIKO
PC C12N1/04, C12N15/00, C12N15/00, C12R1:91);
CC strandedness: Single;

CC	hypothetical: No;
CC	anti-sense: No;
CC	*source: strain-CcmV;
FF	Key
FF	location/Qualifiers
FF	3'UTR

```

FEATURES
source      1. .73
            location/Qualifiers
            /organism="Tobacco mosaic virus
            /db_xref="taxon:12242"
BASE COUNT  21 a      17 c      17 g      18 t      '
ORIGIN

```

Query Match	53.1%	Score 15.4	DB 6	Length 73
Best Local Similarity	52.0%	Pred. No. 1.4e+04		
Matches` 13; Conservative	6	Mismatches	6	Indels 0
				Gaps 0

```
QY      4  gaucucuuuuuguaagccccaagc 28
          | :: :: | : | | | | | | |
Db     43  GCTTATTTCGCTAAGCCCTAGGTC 19
```

RESULT	3				
AR020509/c					
LOCUS	AR020509	33 bp	DNA	linear	PAT 05-DEC-1998
DEFINITION	Sequence	5 from patent US 5789171.			
ACCESSION	AR020509				
VERSION	AR020509.1	GI:3975124			

SOURCE	Unknown.
ORGANISM	Unknown.

REFERENCE 1 (bases 1 to 33)

AUTHORS Smeltzer, M.S.

TITLE Use of cna, inda, indb, and hlb, gene probes for the

strain-specific identification of :
Patent: US 5789171-A 5 04-AUG-1998

FEATURES

Location/Qualifiers

source	1. .33			
BASE COUNT	/organism="unknown"			
ORIGIN	12 a	8 c	7 g	6 t

Query Match	52.4%	Score 15.2;	DB 6;	Length 33;
Best Local Similarity	42.9%	Pred. No. 1.8e+04;		
Matches 12; Conservative	8;	Mismatches 8;	Indels 0;	Gaps 0;

```

QY      2  aagaucuuuuuuaagccccaaggcu 29
          | | | : : : : | | | | :
Db      32  ATGATTGTTTAGTAAATTCGCCGGCT 5

```

RESULT	4
E09974	
ID	E09974
XX	standard; DNA; UNC; 23 BP.

AC	E09974;
XX	
SV	E09974.1
XX	

DT	07-OCT-1997 (Rel. 52, Created)
DT	02-SEP-2000 (Rel. 65, Last updated, Version 2)

DE Primer for amplifying human herpes virus.
XX
KW JP 1995250699-A/20.

XX unidentified
OS unclassified.
OC
XX

RP 1-23
 RT Yamanishi K., Mukai T., Aono T., Kondo M., Takarada Y.;
 RA "METHOD FOR DISCRIMINATORY DETECTION OF HUMAN HERPES VIRUS AND REAGENT
 RT THEREFOR";
 RL Patent number JP1995250699-A/20, 03-OCT-1995.
 RL TOYOCO CO LTD.

XX	OS	None
CC	OC	Artificial sequences.
CC	PN	JP 1995250699-A/20
CC	PD	03-OCT-1995
CC	PF	11-MAR-1994 JP 1994041101

CC	PC	C12Q1/68, C12M15/09, C12Q1/70;
CC	CC	strandedness: Single;
CC	CC	topology: Linear;
CC	CC	

CC	FH	key	Location/Qualifiers
CC	FH		
CC	FT	source	1. .23

CC	FT	/note="Common sequences for human herpes virus
CC	FT	6-type A,
CC	FT	human herpes virus 6-type B, human herpes
CC	FT	virus-7 and
CC	FT	cytomegalovirus"
XX		

FH	
FT	source
	. 1. .23

```
FT /db_xref="taxon:32644"
FT /organism="unidentified"
```

XX

Sequence 23 BP; 5 A; 5 C; 6 G; 7 T; 0 other,

Query Match

51.78; Score 15; DB 23; Length 23;

Query Match 51.0%; Score 14.8; DB 6; Length 29;
Best Local Similarity 42.3%; Pred. No. 2.8e+04;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 gaucuuuuuuaagccccaaggu 29
||: : : : | | | | |
Db 29 GATTATCTTATCATCCACTAGGGCT 4

RESULT 9
LOCUS I34733 29 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 25 from patent US 5599666.
ACCESSION I34733
VERSION I34733.1 GI:2087701
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 29)
AUTHORS Schumm,J.W. and Puers,C.
TITLE Allelic ladders for short tandem repeat loci
JOURNAL Patent: US 5599666-A 25 04-FEB-1997;
FEATURES Location/Qualifiers
source 1..29

BASE COUNT 12 a 4 c 7 g 6 t
ORIGIN

Query Match 51.0%; Score 14.8; DB 6; Length 29;
Best Local Similarity 42.3%; Pred. No. 2.8e+04;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 gaucuuuuuuaagccccaaggu 29
||: : : : | | | | |
Db 29 GATTATCTTATCATCCACTAGGGCT 4

RESULT 10
LOCUS I67987 29 bp DNA linear PAT 04-FEB-1998
DEFINITION Sequence 25 from patent US 5674686.
ACCESSION I67987
VERSION I67987.1 GI:2830109
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 29)
AUTHORS Schumm,J.W. and Puers,C.
TITLE Allelic ladders for short tandem repeat loci
JOURNAL Patent: US 5674686-A 25 07-OCT-1997;
FEATURES Location/Qualifiers
source 1..29

BASE COUNT 12 a 4 c 7 g 6 t
ORIGIN

Query Match 51.0%; Score 14.8; DB 6; Length 29;
Best Local Similarity 42.3%; Pred. No. 2.8e+04;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 gaucuuuuuuaagccccaaggu 29
||: : : : | | | | |
Db 29 GATTATCTTATCATCCACTAGGGCT 4

RESULT 11
LOCUS AR061867 32 bp DNA linear PAT 29-SEP-1999

DEFINITION Sequence 59 from patent US 5843660.
ACCESSION AR061867
VERSION AR061867.1 GI:5989558
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 32)
AUTHORS Schumm,J.W., Micka,K.A. and Rabbach,D.R.
TITLE Multiplex amplification of short tandem repeat loci
JOURNAL Patent: US 5843660-A 59 01-DEC-1998;
FEATURES Location/Qualifiers
source 1..32

BASE COUNT 13 a 4 c 8 g 7 t
ORIGIN

Query Match 51.0%; Score 14.8; DB 6; Length 32;
Best Local Similarity 42.3%; Pred. No. 2.8e+04;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 gaucuuuuuuaagccccaaggu 29
||: : : : | | | | |
Db 29 GATTATCTTATCATCCACTAGGGCT 4

RESULT 12
LOCUS A52215 80 bp DNA linear PAT 12-DEC-1997
DEFINITION Sequence 5 from Patent EP0705842.
ACCESSION A52215
VERSION A52215.1 GI:2833366
KEYWORDS
SOURCE unidentified.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 80)
AUTHORS Bartnik,E.D. and Margerie,D.D.
TITLE Regulated genes by stimulation of chondrocytes with IL-1beta
JOURNAL Patent: EP 0705842-A 5 10-APR-1996;
COMMENT HOECHST AG (DE)
Other publication ZA 9508381 960424
Other publication JP 8191693 960730
Other publication CA 2159957 960407
Other publication AU 3308695 960418.
FEATURES Location/Qualifiers
source 1..80

BASE COUNT 20 a 22 c 17 g 21 t
ORIGIN

Query Match 51.0%; Score 14.8; DB 6; Length 80;
Best Local Similarity 50.0%; Pred. No. 2.7e+04;
Matches 13; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

QY 1 aaaguuuuuuuaagccccaag 26
| | | | | : : : : | | | | |
Db 13 ACAATATTTTATTTGAGGCCCATGG 38

RESULT 13
LOCUS AX043294 25 bp DNA linear PAT 23-NOV-2000
DEFINITION Sequence 860 from Patent W00065088.
ACCESSION AX043294
VERSION AX043294.1 GI:11341902
KEYWORDS
SOURCE synthetic construct.
ORGANISM artificial sequence.

REFERENCE 1 (bases 1 to 25)
AUTHORS Ulfendahl, P.J. and Wong, K.C.
TITLE Primers for identifying typing or classifying nucleic acids
JOURNAL Patent: WO 0065088-A 860 02-NOV-2000;
Amersham Pharmacia Biotech AB (SE)
FEATURES
source Location/Qualifiers
1..25
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="DQAI Heterozygote Primer Sequence"
BASE COUNT 4 a 4 c 3 g 14 t
ORIGIN

Query Match 50.3%; Score 14.6; DB 6; Length 25;
Best Local Similarity 42.9%; Pred. No. 3.4e+04;
Matches 9; Conservative 8; Mismatches 4; Indels 0; Gaps 0;

QY 6 uuuuuuuuagccccaagg 26
Db 5 TTTTGTGTCAGCCACATG 25

RESULT 14
AR061021/c 53 bp DNA linear PAT 29-SEP-1999
LOCUS AR061021
DEFINITION Sequence 46 from patent US 5843456.
ACCESSION AR061021
VERSION AR061021.1 GI:5988712
KEYWORDS
SOURCE
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 53)
AUTHORS Paoletti, E. and Maki, J.
TITLE Alvac poxvirus-rabies compositions and combination compositions and
uses
JOURNAL Patent: US 5843456-A 46 01-DEC-1998;
FEATURES
source Location/Qualifiers
1..53
/organism="unknown"
BASE COUNT 20 a 10 c 10 g 13 t
ORIGIN

Query Match 50.3%; Score 14.6; DB 6; Length 53;
Best Local Similarity 47.6%; Pred. No. 3.4e+04;
Matches 10; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

QY 9 uuuuuuagccccaaggcu 29
Db 29 TTTTGTGAAGCTTCCCGGCT 9

RESULT 15
DDIDDKD/c 87 bp DNA linear INV 27-APR-1993
LOCUS DDIDDKD
DEFINITION D discoidium protein kinase 4 gene, partial cds.
ACCESSION M59747
VERSION M59747.1 GI:167723
KEYWORDS
SOURCE
ORGANISM Dictyostelium discoideum (strain AX-3) DNA.
Dictyostelium discoideum
Eukaryota; Mycetozoa; Dictyostelida; Dictyostelium.
REFERENCE 1 (bases 1 to 87)
AUTHORS Haribabu, B. and Dotti, R.P.
TITLE Identification of a protein kinase multigene family of
Dictyostelium discoideum: Molecular cloning and expression of a
cDNA encoding a developmentally regulated protein kinase
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 88, 1115-1119 (1991)
FEATURES
source Location/Qualifiers
1..87

CDS
/organism="Dictyostelium discoideum"
/strain="AX-3"
/db_xref="taxon:44689"
<1..>87
/codon_start=1
/product="protein kinase 4"
/protein_id="AAA33189.1"
/db_xref="GI:167724"
/translation="NLIDQXGHKLPFGFAKRTTENTKSMC"
BASE COUNT 36 a 12 c 14 g 25 t
ORIGIN

Query Match 50.3%; Score 14.6; DB 3; Length 87;
Best Local Similarity 47.6%; Pred. No. 3.4e+04;
Matches 10; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

QY 4 gauuuuuuuuagcccca 24
Db 63 GATCTTTTGCACATCCAA 43

Search completed: September 13, 2002, 13:18:18
Job time: 4933 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2002, 12:37:52 : Search time 63.83 Seconds
(without alignments)
111.599 Million cell updates/sec

Title: US-09-310-844C-25

Perfect score: 29

Sequence: 1 aaagaucuuuuuuaagcccaaggcu 29

Scoring table:

IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 383533 seqs, 122816752 residues

Total number of hits satisfying chosen parameters: 613726

Minimum DB seq length: 0

Maximum DB seq length: 100

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued_Patents_NA:*
1: /cgn2_6/ptodata/1/ina/5A.COMB.seq:*
2: /cgn2_6/ptodata/1/ina/5B.COMB.seq:*
3: /cgn2_6/ptodata/1/ina/6A.COMB.seq:*
4: /cgn2_6/ptodata/1/ina/6B.COMB.seq:*
5: /cgn2_6/ptodata/1/ina/PTCUTS.COMB.seq:*
6: /cgn2_6/ptodata/1/ina/Backfiles1.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	15.2	52.4	33	1	US-08-667-079B-5
C 2	15.2	52.4	75	1	US-07-971-101-6
C 3	14.8	51.0	29	1	US-08-219-633-25
C 4	14.8	51.0	29	1	US-08-515-236-25
C 5	14.8	51.0	29	1	US-08-761-950-25
C 6	14.8	51.0	29	2	US-08-632-575B-39
C 7	14.8	51.0	29	4	US-09-327-229-31
C 8	14.8	51.0	29	4	PCR-US95-12608-31
C 9	14.8	51.0	32	2	US-08-632-575B-59
C 10	14.6	50.3	53	2	US-08-486-969-46
C 11	14.2	49.0	69	2	US-08-410-654B-30
C 12	14.2	49.0	69	2	US-08-474-851-30
C 13	14.2	49.0	69	2	US-08-481-560-30
C 14	13.8	47.6	41	4	US-08-943-731-336
C 15	13.6	46.9	25	4	US-09-565-156A-2
C 16	13.6	46.9	79	1	US-08-472-255A-136
C 17	13.6	46.9	79	1	US-08-479-724A-136
C 18	13.6	46.9	79	3	US-08-472-256B-136
C 19	13.6	46.9	79	3	US-08-952-793-136
C 20	13.6	46.9	79	5	PCR-US96-09455A-136
C 21	13.6	46.9	82	4	US-09-565-156A-10
C 22	13.6	46.9	82	4	US-09-565-156A-23
C 23	13.6	46.9	93	4	US-09-565-156A-11
C 24	13.6	46.9	93	4	US-09-565-156A-13
C 25	13.6	46.9	93	4	US-09-565-156A-15
C 26	13.4	46.2	32	3	US-08-718-738-16
C 27	13.4	46.2	32	4	US-09-221-844-16

C 28	13.4	46.2	32	5	PCR-US95-03323A-16	Sequence 16, Appl
C 29	13.4	46.2	46	1	US-08-171-389-42	Sequence 42, Appl
C 30	13.4	46.2	46	1	US-08-171-389-45	Sequence 45, Appl
C 31	13.4	46.2	46	1	US-08-123-936-42	Sequence 42, Appl
C 32	13.4	46.2	46	1	US-08-123-936-45	Sequence 45, Appl
C 33	13.4	46.2	46	2	US-08-475-228A-42	Sequence 42, Appl
C 34	13.4	46.2	46	2	US-08-475-228A-45	Sequence 45, Appl
C 35	13.4	46.2	46	3	US-08-482-080A-42	Sequence 42, Appl
C 36	13.4	46.2	46	3	US-08-482-080A-45	Sequence 45, Appl
C 37	13.4	46.2	46	5	PCR-US93-12388-42	Sequence 42, Appl
C 38	13.4	46.2	46	5	PCR-US93-12388-45	Sequence 45, Appl
C 39	13.4	46.2	50	1	US-08-245-754A-13	Sequence 13, Appl
C 40	13.4	46.2	50	1	US-08-171-389-46	Sequence 46, Appl
C 41	13.4	46.2	50	1	US-08-123-936-46	Sequence 46, Appl
C 42	13.4	46.2	50	2	US-08-475-228A-46	Sequence 46, Appl
C 43	13.4	46.2	50	2	US-08-597-731-13	Sequence 13, Appl
C 44	13.4	46.2	50	3	US-08-482-080A-46	Sequence 46, Appl
C 45	13.4	46.2	50	3	PCR-US93-12388-46	Sequence 46, Appl

ALIGNMENTS

RESULT 1
US-08-667-079B-5/c
; Sequence 5, Application US/08667079B
; Patent No. 5789171
; GENERAL INFORMATION:
; APPLICANT: Mark S. Smeltzer
; TITLE OF INVENTION: Use of cna, fnbA, fnbB, and hlb Gene Probes for the Strain-
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Benjamin Aaron Adler, MCGREGOR & ADLER, P.C.
; CITY: Houston
; STREET: 8011 Candle Lane
; STATE: Texas
; COUNTRY: USA
; ZIP: 77071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh
; SOFTWARE: Microsoft Word for Macintosh
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/667,079B
; FILING DATE: June 20, 1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Adler, Benjamin Aaron
; REGISTRATION NUMBER: 35,423
; REFERENCE/DOCKET NUMBER: D5386
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713-777-6908
; TELEFAX: 713-777-2321
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 33
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE:
; DESCRIPTION: other nucleic acid
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; STRAIN:
; INDIVIDUAL ISOLATE:
; DEVELOPMENTAL STAGE:
; TISSUE TYPE:
; CELL TYPE:
; CELL LINE:
; US-08-667-079B-5

TELEPHONE: (608) 257-5353
TELEFAX: (608) 257-9175
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 29 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-515-236-25

Query Match 51.0%; Score 14.8; DB 1; length 29;
Best Local Similarity 42.3%; Pred. No. 2.8e+02;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 gaucuuuuuuaagcccaaggcu 29
||: : : : | | | | |
DB 29 GATTATCTTATCATCACTAGGCT 4

RESULT 5

US-08-761-950-25/C
Sequence 25, Application US/08761950
Patent No. 5783406
GENERAL INFORMATION:
APPLICANT: Schumm, James W.
TITLE OF INVENTION: ALLELIC LADDERS FOR SHORT TANDEM REPEAT
TITLE OF INVENTION: LOCI
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Ross & Stevens, S.C.
STREET: One South Pinckney Street, P.O. Box 2599
CITY: Madison
STATE: Wisconsin
COUNTRY: U.S.A.
ZIP: 53701-2599
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/761,950
FILING DATE: 09-DEC-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/515,236
FILING DATE: 15-AUG-1995
APPLICATION NUMBER: US 08/219,633
FILING DATE: 28-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Sara, Charles S.
REGISTRATION NUMBER: 30,492
REFERENCE/DOCKET NUMBER: 34506.019
TELECOMMUNICATION INFORMATION:
TELEPHONE: (608) 257-5353
TELEFAX: (608) 257-9175
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 29 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-761-950-25

Query Match 51.0%; Score 14.8; DB 1; length 29;
Best Local Similarity 42.3%; Pred. No. 2.8e+02;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;
QY 4 gaucuuuuuuaagcccaaggcu 29
||: : : : | | | | |

DB 29 GATTATCTTATCATCACTAGGCT 4

RESULT 6

US-08-632-575B-39/C
Sequence 39, Application US/08632575B
Patent No. 5843660
GENERAL INFORMATION:
APPLICANT: Schumm, James W.
TITLE OF INVENTION: Multiplex Amplification of
TITLE OF INVENTION: Short Tandem Repeat Loci
NUMBER OF SEQUENCES: 61
CORRESPONDENCE ADDRESS:
ADDRESSEE: Promega Corporation
STREET: 2800 Woods Hollow Road
CITY: Madison
STATE: Wisconsin
COUNTRY: U.S.A.
ZIP: 53711-5399
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 MB
COMPUTER: IBM compatible PC
OPERATING SYSTEM: DOS, version 6.0
SOFTWARE: Wordperfect 5.1 (DOS text format)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/632,575B
FILING DATE: 04/15/96
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/316,544
FILING DATE: 09/30/94
INFORMATION FOR SEQ ID NO: 39:
SEQUENCE CHARACTERISTICS:
LENGTH: 29
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: linear
POSITION IN GENOME:
MAP POSITION: HUMWFA31
US-08-632-575B-39

Query Match 51.0%; Score 14.8; DB 2; length 29;
Best Local Similarity 42.3%; Pred. No. 2.8e+02;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 gaucuuuuuuaagcccaaggcu 29
||: : : : | | | | |
DB 29 GATTATCTTATCATCACTAGGCT 4

RESULT 7

US-09-327-229-31/C
Sequence 31, Application US/09327229
Patent No. 6221598
GENERAL INFORMATION:
APPLICANT: Schumm, James W.
Sprecher, Cynthia J.
Lins, Ann M.
TITLE OF INVENTION: MULTIPLEX AMPLIFICATION OF SHORT TANDEM
REPEAT LOCI
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:
ADDRESSEE: Ross & Stevens, S.C.
STREET: P. O. Box 2599
CITY: Madison
STATE: Wisconsin
COUNTRY: U.S.A.
ZIP: 53701-2599
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/327,229
FILING DATE: 07-Jun-1999
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/316,544
FILING DATE: 30-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: Sara, Charles S.
REGISTRATION NUMBER: 30,492
REFERENCE/DOCKET NUMBER: 34506.022
TELECOMMUNICATION INFORMATION:
TELEPHONE: 608-257-5353
TELEFAX: 608-257-9175
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 29 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 31:
US-09-327-229-31

Query Match 51.0%; Score 14.8; DB 4; Length 29;
Best Local Similarity 42.3%; Pred. No. 2.8e+02;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 gaucuuuuuuagcccaagggu 29
||:::|||||
DB 29 GATTATCTTATCATCCTAGGCGCT 4

RESULT 8
PCT-US95-12608-31/c
Sequence 31, Application PC/TUS9512608
GENERAL INFORMATION:
APPLICANT: Schumm, James W.
APPLICANT: Sprecher, Cynthia J.
APPLICANT: Lins, Ann M.
TITLE OF INVENTION: MULTIPLEX AMPLIFICATION OF SHORT TANDEM
NUMBER OF INVENTIONS: REPEAT LOCI
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:
ADDRESSEE: Ross & Stevens, S.C.
STREET: P. O. Box 2599
CITY: Madison
STATE: Wisconsin
COUNTRY: U.S.A.
ZIP: 53701-2599
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/12608
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Sara, Charles S.
REGISTRATION NUMBER: 30,492
REFERENCE/DOCKET NUMBER: 34506.022
TELECOMMUNICATION INFORMATION:
TELEPHONE: 608-257-5353
TELEFAX: 608-257-9175
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 29 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)
PCT-US95-12608-31

Query Match 51.0%; Score 14.8; DB 5; Length 29;
Best Local Similarity 42.3%; Pred. No. 2.8e+02;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 gaucuuuuuuagcccaagggu 29
||:::|||||
DB 29 GATTATCTTATCATCCTAGGCGCT 4

RESULT 9
US-08-632-575B-59/c
Sequence 59, Application US/08632575B
Patent No. 5843660
GENERAL INFORMATION:
APPLICANT: Schumm, James W.
TITLE OF INVENTION: Multiplex Amplification of
NUMBER OF INVENTIONS: Short Tandem Repeat Loci
NUMBER OF SEQUENCES: 61
CORRESPONDENCE ADDRESS:
ADDRESSEE: Promega Corporation
STREET: 2800 Woods Hollow Road
CITY: Madison
STATE: Wisconsin
COUNTRY: U.S.A.
ZIP: 53711-5399

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 MB
COMPUTER: IBM compatible PC
OPERATING SYSTEM: DOS, version 6.0
SOFTWARE: Wordperfect 5.1 (DOS text format)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/632,575B
FILING DATE: 04/15/96

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/316,544
FILING DATE: 09/30/94
INFORMATION FOR SEQ ID NO: 59:
SEQUENCE CHARACTERISTICS:
LENGTH: 32
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: linear
POSITION IN GENOME:
MAP POSITION: HUMWFA31
US-08-632-575B-59

Query Match 51.0%; Score 14.8; DB 2; Length 32;
Best Local Similarity 42.3%; Pred. No. 2.8e+02;
Matches 11; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

QY 4 gaucuuuuuuagcccaagggu 29
||:::|||||
DB 29 GATTATCTTATCATCCTAGGCGCT 4

RESULT 10
US-08-486-969-46/c
Sequence 46, Application US/08486969
Patent No. 5843456
GENERAL INFORMATION:
APPLICANT: Paoletti, Enzo
APPLICANT: Maki, Joanne
TITLE OF INVENTION: RECOMBINANT POXYVIRUS - RABIES
NUMBER OF INVENTIONS: COMPOSITIONS AND COMBINATION COMPOSITIONS AND USES
CORRESPONDENCE ADDRESS:
ADDRESSEE: Curtiss, Morris & Safford, P.C.

STREET: 530 Fifth Avenue, 25th Floor
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/486,969
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Frommer, William S.
REGISTRATION NUMBER: 25,506
REFERENCE/DOCKET NUMBER: 454310-2600
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 840-3333
TELEFAX: (212) 840-0712
INFORMATION FOR SEQ ID NO: 46:
SEQUENCE CHARACTERISTICS:
LENGTH: 53 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-486-969-46

Query Match 50.3%; Score 14.6; DB 2; Length 53;
Best Local Similarity 47.6%; Pred. No. 3.8e+02;
Matches 10; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

Qy 9 uuuuuagaccccaaggcu 29
Db 29 TTTTGTAACTTCCCGGCT 9

RESULT 11
US-08-410-654B-30
Sequence 30, Application US/08410654B
Patent No. 5833976
GENERAL INFORMATION:
APPLICANT: Rene de Waal Malefyt
APPLICANT: Di-Hwei Hsu
APPLICANT: Anne O'Garra
TITLE OF INVENTION: Use of Interleukin-10 to Treat
TITLE OF INVENTION: Septic Shock
NUMBER OF SEQUENCES: 61
CORRESPONDENCE ADDRESS:
ADDRESSEE: Schering-Plough Corporation
STREET: 2000 Galloping Hill Road
CITY: Kenilworth
STATE: New Jersey
COUNTRY: USA
ZIP: 07033
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Macintosh
OPERATING SYSTEM: 7.5.3
SOFTWARE: Microsoft Word 5.1a
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/410,654B
FILING DATE: 24-MAR-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/229,854
FILING DATE: 19-APR-1994
APPLICATION NUMBER: US 07/926,853
FILING DATE: 06-AUG-1992

APPLICATION NUMBER: US 07/742,129
FILING DATE: 06-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Foulke, Cynthia L.
REGISTRATION NUMBER: 32,364
REFERENCE/DOCKET NUMBER: DX0221KQ1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 908-298-2987
TELEFAX: 908-298-5388
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 69 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (oligonucleotide)
US-08-410-654B-30

Query Match 49.0%; Score 14.2; DB 2; Length 69;
Best Local Similarity 51.9%; Pred. No. 6.1e+02;
Matches 14; Conservative 5; Mismatches 8; Indels 0; Gaps 0;

Qy 1 aaagaucuuuuuagaccccaagg 27
Db 7 AAGATGCCTTAATAGCTCCAGAG 33

RESULT 12
US-08-474-851-30
Sequence 30, Application US/08474851
Patent No. 5837232
GENERAL INFORMATION:
APPLICANT: Rene de Waal Malefyt
APPLICANT: Di-Hwei Hsu
APPLICANT: Anne O'Garra
TITLE OF INVENTION: Use of An Interleukin-10 Antagonist to Treat
TITLE OF INVENTION: A B Cell Mediated Autoimmune Disorder
NUMBER OF SEQUENCES: 61
CORRESPONDENCE ADDRESS:
ADDRESSEE: Schering-Plough Corporation
STREET: 2000 Galloping Hill Road
CITY: Kenilworth
STATE: New Jersey
COUNTRY: USA
ZIP: 07033
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Macintosh
OPERATING SYSTEM: 7.5.3
SOFTWARE: Microsoft Word 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/474,851
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/410,654
FILING DATE: 24-MAR-1995
APPLICATION NUMBER: US 08/229,854
FILING DATE: 19-APR-1994
APPLICATION NUMBER: US 07/926,853
FILING DATE: 06-AUG-1992
APPLICATION NUMBER: US 07/742,129
FILING DATE: 06-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: Foulke, Cynthia L.
REGISTRATION NUMBER: 32,364
REFERENCE/DOCKET NUMBER: DX0221KQ1GD
TELECOMMUNICATION INFORMATION:
TELEPHONE: 908-298-2987
TELEFAX: 908-298-5388
INFORMATION FOR SEQ ID NO: 30:

Db 22 ATCTCTTGTGTGAGCCC 6

RESULT 15

US-09-565-156A-2
 ; Sequence 2, Application US/09565156A
 ; Patent No. 6326486
 ; GENERAL INFORMATION:
 ; APPLICANT: Hogan, James J.
 ; APPLICANT: Gordon, Patricia
 ; TITLE OF INVENTION: Polynucleotide probes for detection and
 ; FILE REFERENCE: GP110-02.UT
 ; CURRENT APPLICATION NUMBER: US/09/565,156A
 ; CURRENT FILING DATE: 2000-05-03
 ; PRIOR APPLICATION NUMBER: 60/132,410
 ; PRIOR FILING DATE: 1999-05-03
 ; NUMBER OF SEQ ID NOS: 23
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 2
 ; LENGTH: 41
 ; TYPE: DNA
 ; ORGANISM: Enterobacteriaceae
 US-09-565-156A-2

Query Match 45.9%; Score 13.6; DB 4; Length 41;
 Best Local Similarity 45.0%; Pred. No. 1e+03;
 Matches 9; Conservative 7; Mismatches 4; Indels 0; Gaps 0;
 QY 4 gaucuuuuuuaagccca 23
 |::|::|::|::|::|::|
 Db 4 gcttctcttgatgcgcca 23

Search completed: September 13, 2002, 12:37:53
 Job time: 9818 sec

THIS PAGE BLANK (USPTO)

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2002, 12:36:31 : Search time 2238.85 Seconds
(without alignments)
174.827 Million cell updates/sec

Title: US-09-310-844C-25

Perfect score: 29

Sequence: 1 aaagaucuuuuuuaagcccaaggagcu 29

Scoring table: IDENTITY_NUC

Gapop 10.0, Gapext 1.0

Searched: 13736207 seqs, 6748477542 residues

Total number of hits satisfying chosen parameters: 297742

Minimum DB seq length: 0

Maximum DB seq length: 100

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :
EST:
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estnu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hlc:*
9: gb_est1:*
10: gb_est2:*
11: gb_hlc:*
12: gb_gss:*
13: em_gss_hum:*
14: em_gss_inv:*
15: em_gss_pln:*
16: em_gss_vrt:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	18.4	63.4	67	9	AA516989 v089d02.r
2	17.4	60.0	96	9	AA708811 AA708911 z16a10.s
3	17.4	60.0	96	12	A2786158 2M0031E01
4	16.8	57.9	100	10	H13396 EST00022.ch
5	16.6	57.2	70	9	AI609394 tw93b03.x
6	16.6	57.2	75	10	H07686 H07686 khg012.BNL
7	16	55.2	51	10	BC361927 gba9d10.y
8	16	55.2	73	10	BC361878 BC361878 gba6b10.y
9	16	55.2	83	10	BC361896 BC361896 gba6d08.y
10	16	55.2	83	10	BC362080 BC362080 gba7d02.y
11	15.8	54.5	90	10	BE959933 BE959933 601654678
12	15.8	54.5	58	9	AI824019 AI824019 wj29f03.x
13	15.8	54.5	76	12	A2657549 A2657549 1M0533118
14	15.6	53.8	37	9	AI802260 f136g07.x
15	15.6	53.8	38	12	A2834846 2M0117F18
16	15.6	53.8	86	12	CNS0210D AI199174 Tetradon
17	15.6	53.8	96	10	BF730561 mab72e11.

18	15.4	53.1	49	10	U44334
19	15.4	53.1	77	12	BH252676 BH252676 SALK_0137
20	15.4	53.1	81	12	A2983583 A2983583 2M0264J16
21	15.4	53.1	86	10	D25962 HUMG506736
22	15.4	53.1	89	9	AA709006 AA709006 z194h07.s
23	15.4	53.1	86	9	AM641294 AM641294 cm05g04.w
24	15.4	53.1	97	9	AA207690 AA207690 mv79b04.r
25	15.2	52.4	61	9	AI18033 AI18033 ta75g02.x
26	15.2	52.4	78	9	AA936218 AA936218 on43c10.s
27	15.2	52.4	98	9	AM311302 AM311302 sg35b11.y
28	15	51.7	58	12	B02943 B02943 CSR-163G2-
29	15	51.7	89	10	BG223126 BG223126 nah43h02.
30	14.8	51.0	34	12	A2840876 A2840876 2M0138C08
31	14.8	51.0	49	12	A2576537 A2576537 ASR-T11C0
32	14.8	51.0	55	9	AI224478 AI224478 qx06d06.x
33	14.8	51.0	64	10	BE636255 BE636255 SMOVACACQ
34	14.8	51.0	85	9	AA617776 AA617776 np99e08.s
35	14.8	51.0	88	12	A2875397 A2875397 2M0189E08
36	14.8	51.0	95	9	AI669223 AI669223 wc13d10.x
37	14.6	50.3	59	10	BE970792 BE970792 601680150
38	14.6	50.3	71	12	A2833202 A2833202 2M0115E08
39	14.6	50.3	75	9	AI696772 AI696772 wc61d07.x
40	14.6	50.3	82	12	A2817220 A2817220 2M0086M20
41	14.6	50.3	85	10	BF711373 BF711373 MI-P-A1-a
42	14.4	49.7	37	12	A2950243 A2950243 2M0214C15
43	14.4	49.7	41	12	A2598587 A2598587 1M0413A04
44	14.4	49.7	57	10	EG362067 EG362067 gba7b08.y
45	14.4	49.7	64	9	AI321110 AI321110 d4c09mm.r

ALIGNMENTS

RESULT 1
LOCUS AA516989/c
DEFINITION v089d02.r1 Knowles Solter mouse embryonic stem cell Mus musculus
CDNA clone IMAGE:894147 5' similar to TR:G187568 G187568 MC44 ;
mRNA sequence.

ACCESSION AA516989
VERSION AA516989.1 GI:2256448
KEYWORDS
SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE
AUTHORS Marra, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T., Geisler, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M., Schellenberg, K., Steptoe, M., Tan, F., Underwood, K., Moore, B., Theising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and Waterston, R.

TITLE The WashU-HMI Mouse EST Project
JOURNAL Unpublished (1996)
COMMENT Contact: Marra M/Mouse EST Project
WashU-HMI Mouse EST Project

Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@wustl.wustl.edu
This clone is available royalty-free through LNL; contact the
IMAGE Consortium (info@image.lnl.gov) for further information.
WGI:522107
Trace considered overall poor quality
Possible reversed clone; similarity on wrong strand
High quality sequence stop: 1.
Location/Qualifiers
1..70
/organism="Mus musculus"
/strain="B6D2 F1/J"
/db_xref="taxon:10090"
/clone="IMAGE:894147"

/clone.lib="Knowles Solter mouse embryonic stem cell"
 /dev_stage="embryo"
 /lab_host="DH10B"
 /note="Vector: pSPORT; Site.1: NotI; Site.2: SalI; Cloned unidirectionally from mRNA prepared from 800 blastocysts. Primer: SalI(drf): 5'-GGTCGACCGCGACCGCTTTTCTTTT-3'. cDNAs were cloned into the NotI/SalI sites of a pSPORT vector (Life Technologies)."
 BASE COUNT 16 a 14 c 15 g 25 t
 ORIGIN

Query Match 63.4%; Score 18.4; DB 9; Length 70;
 Best Local Similarity 57.1%; Pred. No. 7.8e+03;
 Matches 16; Conservative 6; Mismatches 6; Indels 0; Gaps 0;

OY 1 aaagaunuuuuuagagcccaaggac 28
 |||:::|||||
 Db 47 ACAGATTCTTTAGAACACCAAGGAC 20

RESULT 2
 LOCUS AA708911 67 bp mRNA linear EST 24-DEC-1997
 DEFINITION Z16410.s1 Soares.pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:506682 3 similar to SW:RB32_HUMAN Q13637 RAS-RELATED PROTEIN RAB-32; mRNA sequence.

AA708911

AA708911.1 GI:2718829

EST.

human.

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

1 (bases 1 to 67)

Hillier, L., Allen, M., Bowles, L., Dubuque, T., Geisels, G., Jost, S.,

Kritman, D., Kucaba, T., Lacy, M., Le, N., Lennon, G., Maita, M., Martin

, J., Moore, B., Schellenberg, K., Steptoe, M., Tan, F., Theising, B.,

White, Y., Wylie, T., Waterston, R. and Wilson, R.

White, Y., Wylie, T., Waterston, R. and Wilson, R.

White, Y., Wylie, T., Waterston, R. and Wilson, R.

White, Y., Wylie, T., Waterston, R. and Wilson, R.

White, Y., Wylie, T., Waterston, R. and Wilson, R.

White, Y., Wylie, T., Waterston, R. and Wilson, R.

White, Y., Wylie, T., Waterston, R. and Wilson, R.

White, Y., Wylie, T., Waterston, R. and Wilson, R.

White, Y., Wylie, T., Waterston, R. and Wilson, R.

White, Y., Wylie, T., Waterston, R. and Wilson, R.

White, Y., Wylie, T., Waterston, R. and Wilson, R.

White, Y., Wylie, T., Waterston, R. and Wilson, R.

White, Y., Wylie, T., Waterston, R. and Wilson, R.

White, Y., Wylie, T., Waterston, R. and Wilson, R.

White, Y., Wylie, T., Waterston, R. and Wilson, R.

White, Y., Wylie, T., Waterston, R. and Wilson, R.

White, Y., Wylie, T., Waterston, R. and Wilson, R.

/clone.lib="Knowles Solter mouse embryonic stem cell"
 /dev_stage="embryo"
 /lab_host="DH10B"
 /note="Vector: pSPORT; Site.1: NotI; Site.2: SalI; Cloned unidirectionally from mRNA prepared from 800 blastocysts. Primer: SalI(drf): 5'-GGTCGACCGCGACCGCTTTTCTTTT-3'. cDNAs were cloned into the NotI/SalI sites of a pSPORT vector (Life Technologies)."
 BASE COUNT 16 a 14 c 15 g 25 t
 ORIGIN

Query Match 60.0%; Score 17.4; DB 9; Length 67;
 Best Local Similarity 55.6%; Pred. No. 1.8e+04;
 Matches 15; Conservative 6; Mismatches 6; Indels 0; Gaps 0;

OY 3 agauuuuuuuuagagcccaaggac 29
 |||:::|||||
 Db 51 ACAGACTTCTTTAGAACCCCAAGGCT 25

RESULT 3
 LOCUS AZ786158 96 bp DNA linear GSS 16-FEB-2001
 DEFINITION 2M0031E01R Mouse 10kb plasmid UGCC1M library Mus musculus genomic clone UGCC2M0031E01 R, DNA sequence.

AZ786158

AZ786158.1 GI:12923638

GSS.

house mouse.

ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

AUTHORS Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1 (bases 1 to 96)

Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C.,

Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly

, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausen, A.

and Wright, D., Weiss, R.

Mouse whole genome scaffolding with paired end reads from 10kb

plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah Genome Center

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0031 row: E column: 01

Seq primer: CACACAGGAACACGATATACC

Class: plasmid ends

High quality sequence stop: 96.

Location/Qualifiers

/organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone.lib="UUGC2M0031E01"
 /clone.lib="Mouse 10kb plasmid UGCC1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PMD29v. Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g11473211419b/AF129072.1), a copy number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 60.0%; Score 17.4; DB 9; Length 67;
 Best Local Similarity 55.6%; Pred. No. 1.8e+04;
 Matches 15; Conservative 6; Mismatches 6; Indels 0; Gaps 0;

OY 3 agauuuuuuuuagagcccaaggac 29
 |||:::|||||
 Db 51 ACAGACTTCTTTAGAACCCCAAGGCT 25

RESULT 3
 LOCUS AZ786158 96 bp DNA linear GSS 16-FEB-2001
 DEFINITION 2M0031E01R Mouse 10kb plasmid UGCC1M library Mus musculus genomic clone UGCC2M0031E01 R, DNA sequence.

AZ786158

AZ786158.1 GI:12923638

GSS.

house mouse.

ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

AUTHORS Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1 (bases 1 to 96)

Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C.,

Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly

, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausen, A.

and Wright, D., Weiss, R.

Mouse whole genome scaffolding with paired end reads from 10kb

plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah Genome Center

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0031 row: E column: 01

Seq primer: CACACAGGAACACGATATACC

Class: plasmid ends

High quality sequence stop: 96.

Location/Qualifiers

```

BASE COUNT      39 a      25 c      19 g      13 t
ORIGIN
Query Match      60.0%; Score 17.4; DB 12; Length 96;
Best Local Similarity 48.1%; Pred. No. 1.7e+04;
Matches 13; Conservative 8; Mismatches 6; Indels 0; Gaps 0;

OY      3  agauuuuuuuuagcccaaggcu 29
      ||:::|||||:::|||||
Db      54  AGTTCTTTTGAGAGCAGCGGCT 28

RESULT 4
LOCUS      H13996      100 bp      mRNA      linear      EST 03-JUL-1995
DEFINITION EST00022 Chromosome 19p12-p13.1 exon Homo sapiens cDNA clone G3-8
ACCESSION  H13996
VERSION     H13996.1 GI:888005
KEYWORDS   EST.
SOURCE      human.
ORGANISM    Homo sapiens
REFERENCE    1 (bases 1 to 100)
AUTHORS      L1,Q.Y.
TITLE        Chromosome 19p12-p13.1 exons
JOURNAL      Unpublished (1995)
COMMENT      Contact: L1 OY
              Human Molecular Genetics
              Queen's Medical Centre
              Nottingham, NG7 2UH, UK
              Tel: 1158249924
              Fax: 1159709906
              Email: pdazy@pdm1.gene.nottingham.ac.uk
              Seq primer: SD2 : 5' ATC TCA GTG GTA TTT GTC AGC 3'.
              Location/Qualifiers
                1..100
                /organism="Homo sapiens"
                /db_xref="taxon:9606"
                /map="19p12-p13.1"
                /clone="C3-8"
                /clone_lib="Chromosome 19p12-p13.1 exon"
                /lab_host="E. coli DH5a"
                /note="Vector: pAMP10; Exons were isolated from human
                chromosome 19p12-p13.1 specific cosmid from Lawrence
                Livermore National Laboratory using a modification of the
                method of exon amplification (Proc. Natl. Acad. Sci. USA
                88: 4005-4009, 1991). Amplified exons were cloned into
                pAMP10 by uracil cloning (GIBCO BRL)."
```

```

SOURCE      human.
ORGANISM    Homo sapiens
REFERENCE    1 (bases 1 to 70)
AUTHORS      NCI/NIH-CGAP
TITLE        NCI/NIH-CGAP http://www.ncbi.nlm.nih.gov/ncicgap
JOURNAL      National Cancer Institute / National Institute of Dental Research,
              Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
              Unpublished (1997)
COMMENT      Contact: Robert Strausberg, Ph.D.
              Email: cgaps@mail.nih.gov
              Tissue Procurement: Chong Heon Lee, D.D.S., Mary May, J. Silvio
              Gutkind, Ph.D., Myung Hee Park, Ph.D.
              CDNA Library Preparation: Stratagene, Inc.
              CDNA Library Arrayed by: Greg Lennon, Ph.D.
              DNA Sequencing by: Washington University Genome Sequencing Center
              Clone distribution: NCI-CGAP clone distribution information can be
              found through the I.M.A.G.E. Consortium/LLNL at:
              www-bio.llnl.gov/bdrrp/image/image.html

FEATURES
SOURCE      1..70
              Location/Qualifiers
                /organism="Homo sapiens"
                /db_xref="taxon:9606"
                /clone="IMAGE:2267213"
                /clone_lib="NCI CGAP HN6"
                /tissue_type="normal gingiva (cell line from immortalized
                keratinocytes)"
                /lab_host="SOLR (kanamycin resistant)"
                /note="Vector: Bluescript SK-; Site: EcoRI; Site 2: XhoI
                ; Cloned unidirectionally. Primer: Oligo dT. Average
                insert size 1.3 kb. 5' adaptor sequence: 5' AATTCGACAGAG
                3'
                sequence: 5' (GA)10ACTACTCTCGAGCTTTTCTTTTCTTTT 3' EcoRI
                site appears to have been lost in a fraction of the
                clones. Library constructed by Stratagene; available
                through Mary May, PhD (Oral and Pharyngeal Cancer Branch,
                National Institute of Dental and Craniofacial Research,
                NIH; may@yoda.nidcr.nih.gov)."
```

```

BASE COUNT      18 a      23 c      14 g      12 t      3 others
ORIGIN
Query Match      57.2%; Score 16.6; DB 9; Length 70;
Best Local Similarity 47.8%; Pred. No. 3.6e+04;
Matches 11; Conservative 8; Mismatches 4; Indels 0; Gaps 0;

OY      6  uuuuuuuuuuagcccaaggcu 28
      :::::|||||:::|||||
Db      54  TTTTCTTTGTGGGCCCAAGGCC 32

RESULT 6
LOCUS      H07686      75 bp      mRNA      linear      EST 23-JUN-1995
DEFINITION Hbs012 BNL1 Brassica napus cDNA 3', mRNA sequence.
ACCESSION  H07686
VERSION     H07686.1 GI:872508
KEYWORDS   EST.
SOURCE      rape.
ORGANISM    Brassica napus
REFERENCE    1 (bases 1 to 75)
AUTHORS      Sohn,U., Lee,C.M., Cho,K.H., Jeon,Y.H., Hahn,T.R. and Nam,H.G.
TITLE        CDNAs from Brassica napus (rape)
JOURNAL      Unpublished (1995)
```

COMMENT

Contact: Uik Sohn
 Laboratory of Molecular Biology
 Kyungpook National University
 Dept. of Genetic Eng., Kyungpook National Univ., Taegu 702-701, Korea
 Tel: 0539505382
 Fax: 0539555327
 Email: usohn@h.kyungpook.ac.kr
 EST is putatively homologous to unknown gene
 Seq primer: M13 forward.

FEATURES

source

Location/Qualifiers

1. 75

/organism="Brassica napus"

/strain="cv. Naehan"

/db_xref="taxon:3708"

/clone_lib="BNL1"

/lab_host="NM522"

/note="Vector: pT73D; Site_1: NotI; Site_2: EcoRI; Poly(A) library was purified from the leaf of B.napus. cDNA library was constructed from the mRNAs by oligo(dT) priming and directionally cloned from the NotI site in the vector pT73D (Pharmacia) to the EcoRI site."

BASE COUNT

20 a 20 c 14 g 21 t

ORIGIN

Query Match 57.2%; Score 16.6; DB 10; Length 75;
 Best Local Similarity 56.5%; Pred. No. 3.5e+04;
 Matches 13; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

QY 7 uuuuuuuaagcccaagcgc 29

Db 34 TCTTCTTGAAGCTCCAGGCTT 12

RESULT 7
 BG361927/c 51 bp mRNA linear EST 08-MAR-2001
 LOCUS 9b49d10.y1 Moss EST library ppg Physcomitrella patens cDNA clone

DEFINITION PEP_SOURCE_ID: 5', mRNA sequence.

ACCESSION BG361927

VERSION BG361927.1 GI:13251024

KEYWORDS EST.

SOURCE Physcomitrella patens.

ORGANISM Physcomitrella patens.

REFERENCE Bryopsida; Viridiplantae; Streptophyta; Embryophyta; Bryophyta;

AUTHORS Quatrano, R., Bashlades, S., Cove, D., Cumling, A., Knight, C., Clifton

S., Merritt, M., Hillier, L., Pape, D., Martin, J., Wylie, T., Underwood

, K., Theising, B., Allen, M., Bowers, Y., Person, B., Swaller, T.,

Steploe, M., Gibbons, M., Harvey, N., Ritter, E., Jackson, Y., McCann, R.,

Leeds/Wash U Moss EST Project

Unpublished (1999)

CONTACT: Ralph Quatrano

Leeds/Wash U Moss EST Project

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA

Tel: 314 286 1800

Fax: 314 286 1810

Email: est@wustl.edu

Libraries were constructed by Dr. Stavros Bashlades as part of the

Physcomitrella EST program (PEP) at the Univ. of Leeds (UK) and

Washington Univ. in St. Louis (USA) DNA sequencing by: Washington

University Genome Sequencing Center For information on obtaining a

clone please contact: Celia Knight (c.d.knight@leeds.ac.uk)
 Seq primer: -40RP from Gibco.

Location/Qualifiers

1. 51

/organism="Physcomitrella patens"

/db_xref="taxon:3218"

/clone="PEP_SOURCE_ID:"

/clone_lib="Moss EST library ppg"

/tissue_type="gametophore: 30 day old tissue,
 ammonium-grown"
 /lab_host="DHI0B"

/note="Vector: PAMP1; Construction of the cDNA library was

performed by Dr. W. Gregg Clark using a modification of

the cDNA synthesis protocol developed in the laboratory of

Dr. Michael Lovett by Dr. Yulia Korshunova (personal

communication). First polyA + RNA was isolated from total

gametophore RNA using oligo dT magnetic beads. Following

this, first strand cDNA synthesis was performed on the

bead-bound polyA + RNA, during which an oligonucleotide

anchor sequence was incorporated onto the 5' ends of the

cDNA. PCR amplification was then used to synthesize the

second strand, to amplify the double stranded DNA, and to

incorporate dUTP containing sequences into the ends of the

double stranded cDNA. This DNA was size selected and

cloned into PAMP1 using the CloneAMP PAMP1 system (Life

Technologies, GibcoBRL) for cloning amplification products

by a non-restriction site dependent process. The cloning

was directional based on sequence asymmetry introduced at

the ends during PCR amplification. The 3' cDNA ends are

proximal to the NotI site of the multiple cloning site in

PAMP1. This annealing mixture was transformed into

chemically competent DH10B cells and selected for

ampicillin resistant growth. The resulting clones (about

330,000) were pooled to make the library."

BASE COUNT

18 a 9 c 8 g 16 t

ORIGIN

Query Match 55.2%; Score 16; DB 10; Length 51;
 Best Local Similarity 41.7%; Pred. No. 6.3e+04;
 Matches 10; Conservative 9; Mismatches 5; Indels 0; Gaps 0;

QY 6 uuuuuuuaagcccaagcgc 29

Db 27 TTTTCTTTTGAAGCTCCAGGCTT 4

RESULT 8
 BG361878/c 73 bp mRNA linear EST 08-MAR-2001
 LOCUS 9b46b10.y1 Moss EST library ppg Physcomitrella patens cDNA clone

DEFINITION PEP_SOURCE_ID: 5', mRNA sequence.

ACCESSION BG361878

VERSION BG361878.1 GI:13250975

KEYWORDS EST.

SOURCE Physcomitrella patens.

ORGANISM Physcomitrella patens.

REFERENCE Bryopsida; Viridiplantae; Streptophyta; Embryophyta; Bryophyta;

AUTHORS Quatrano, R., Bashlades, S., Cove, D., Cumling, A., Knight, C., Clifton

S., Merritt, M., Hillier, L., Pape, D., Martin, J., Wylie, T., Underwood

, K., Theising, B., Allen, M., Bowers, Y., Person, B., Swaller, T.,

Steploe, M., Gibbons, M., Harvey, N., Ritter, E., Jackson, Y., McCann, R.,

Leeds/Wash U Moss EST Project

Unpublished (1999)

CONTACT: Ralph Quatrano

Leeds/Wash U Moss EST Project

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA

Tel: 314 286 1800

Fax: 314 286 1810

Email: est@wustl.edu

Libraries were constructed by Dr. Stavros Bashlades as part of the

Physcomitrella EST program (PEP) at the Univ. of Leeds (UK) and

Washington Univ. in St. Louis (USA) DNA sequencing by: Washington

University Genome Sequencing Center For information on obtaining a

clone please contact: Celia Knight (c.d.knight@leeds.ac.uk)
 Seq primer: -40RP from Gibco.

Location/Qualifiers

1. 51

/organism="Physcomitrella patens"

source

1.73

/organism="Physcomitrella patens"

/db_xref="taxon:3218"

/clone="PEP_SOURCE_ID:"

/clone_lib="Moss EST library PPG"

/tissue_type="gametophore: 30 day old tissue,

ammonium-grown"

/lab_host="DH10B"

/note="Vector: pAMP1. Construction of the cDNA library was performed by Dr. W. Gregg Clark using a modification of the cDNA synthesis protocol developed in the laboratory of Dr. Michael Lovett by Dr. Yulia Korshunova (personal communication). First polyA + RNA was isolated from total gametophore RNA using oligo dT magnetic beads. Following this, first strand cDNA synthesis was performed on the bead-bound polyA + RNA, during which an oligonucleotide anchor sequence was incorporated onto the 5'-ends of the cDNA. PCR amplification was then used to synthesize the second strand, to amplify the double stranded DNA, and to incorporate dUTP containing sequences into the ends of the double stranded cDNA. This DNA was size selected and cloned into pAMP1 using the CloneAMP PAMP1 System (Life Technologies, GibcoBRL) for cloning amplification products by a non-restriction site dependant process. The cloning was directional based on sequence asymmetry introduced at the ends during PCR amplification. The 3' cDNA ends are proximal to the NotI site of the multiple cloning site in pAMP1. This annealing mixture was transformed into chemically competent DH10B cells and selected for ampicillin resistant growth. The resulting clones (about 330,000) were pooled to make the library."

BASE COUNT 24 a 15 c 13 g 21 t

ORIGIN

Query Match 55.2%; Score 16; DB 10; Length 73;

Best Local Similarity 45.8%; Pred. No. 5.9e+04;

Matches 11; Conservative 8; Mismatches 5; Indels 0; Gaps 0;

QY 6 uucuuuuuuaagccccaagggcu 29

DB 40 TTTTGTGGAGAGCCCAAGACT 17

RESULT 9

PG361896/c

LOCUS 83 bp mRNA linear EST 08-MAR-2001

DEFINITION gb46d08.y1 Moss EST library PPG Physcomitrella patens cDNA clone

ACCESSION BG361896

VERSION BG361896

KEYWORDS EST.

SOURCE Physcomitrella patens.

ORGANISM Physcomitrella patens.

REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Bryophyta; Bryopsida; Funariidae; Funariales; Funariaceae; Physcomitrella. 1 (bases 1 to 83)

AUTHORS Quatrano,R., Bashirades,S., Cove,D., Cuning,A., Knight,C., Clifton,S., Marra,M., Hillier,L., Pape,D., Martin,J., Wylie,T., Underwood,K., Theising,B., Allen,M., Bowers,Y., Person,B., Swaller,T., Steptoe,M., Gibbons,M., Harvey,N., Ritter,E., Jackson,Y., McCann,R., Waterston,R. and Wilson,R.

LEADS/Wash U Moss EST Project

Unpublished (1999)

CONTACT: Ralph Quatrano

Leeds/Wash U Moss EST Project

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA

Tel: 314 286 1800

Fax: 314 286 1810

Email: est@wustl.edu

LIBRARIES were constructed by Dr. Stavros Bashirades as part of the Physcomitrella EST program (PEP) at the Univ. of Leeds (UK) and

Washington Univ. in St. Louis (USA) DNA sequencing by: Washington University Genome Sequencing Center For information on obtaining a clone please contact: Celia Knight (c.d.knight@leeds.ac.uk)

Seq primer: -40RP from Gldco.

Location/Qualifiers

1.83

FEATURES

source

1.73

/organism="Physcomitrella patens"

/db_xref="taxon:3218"

/clone="PEP_SOURCE_ID:"

/clone_lib="Moss EST library PPG"

/tissue_type="gametophore: 30 day old tissue,

ammonium-grown"

/lab_host="DH10B"

/note="Vector: pAMP1. Construction of the cDNA library was performed by Dr. W. Gregg Clark using a modification of the cDNA synthesis protocol developed in the laboratory of Dr. Michael Lovett by Dr. Yulia Korshunova (personal communication). First polyA + RNA was isolated from total gametophore RNA using oligo dT magnetic beads. Following this, first strand cDNA synthesis was performed on the bead-bound polyA + RNA, during which an oligonucleotide anchor sequence was incorporated onto the 5'-ends of the cDNA. PCR amplification was then used to synthesize the second strand, to amplify the double stranded DNA, and to incorporate dUTP containing sequences into the ends of the double stranded cDNA. This DNA was size selected and cloned into pAMP1 using the CloneAMP PAMP1 System (Life Technologies, GibcoBRL) for cloning amplification products by a non-restriction site dependant process. The cloning was directional based on sequence asymmetry introduced at the ends during PCR amplification. The 3' cDNA ends are proximal to the NotI site of the multiple cloning site in pAMP1. This annealing mixture was transformed into chemically competent DH10B cells and selected for ampicillin resistant growth. The resulting clones (about 330,000) were pooled to make the library."

BASE COUNT 31 a 11 c 15 g 26 t

ORIGIN

Query Match 55.2%; Score 16; DB 10; Length 83;

Best Local Similarity 41.7%; Pred. No. 5.7e+04;

Matches 10; Conservative 9; Mismatches 5; Indels 0; Gaps 0;

QY 6 uucuuuuuuaagccccaagggcu 29

DB 37 TTTTGTGTAATCCCAAGACT 14

RESULT 10

PG362080/c

LOCUS 83 bp mRNA linear EST 08-MAR-2001

DEFINITION gb47d02.y1 Moss EST library PPG Physcomitrella patens cDNA clone

ACCESSION BG362080

VERSION BG362080

KEYWORDS EST.

SOURCE Physcomitrella patens.

ORGANISM Physcomitrella patens.

REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Bryophyta; Bryopsida; Funariidae; Funariales; Funariaceae; Physcomitrella. 1 (bases 1 to 83)

AUTHORS Quatrano,R., Bashirades,S., Cove,D., Cuning,A., Knight,C., Clifton,S., Marra,M., Hillier,L., Pape,D., Martin,J., Wylie,T., Underwood,K., Theising,B., Allen,M., Bowers,Y., Person,B., Swaller,T., Steptoe,M., Gibbons,M., Harvey,N., Ritter,E., Jackson,Y., McCann,R., Waterston,R. and Wilson,R.

LEADS/Wash U Moss EST Project

Unpublished (1999)

CONTACT: Ralph Quatrano

Leeds/Wash U Moss EST Project

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA

Tel: 314 286 1800
 Fax: 314 286 1810
 Email: est@watson.wustl.edu
 Libraries were constructed by Dr. Stavros Bashlaredes as part of the Physcomitrella EST program (PEP) at the Univ. of Leeds (UK) and Washington Univ. in St. Louis (USA). DNA sequencing by: Washington University Genome Sequencing Center. For information on obtaining a clone please contact: Celia Knight (c.d.knight@leeds.ac.uk)
 Seq primer: -40RP from gibco.

FEATURES

source

1. 83

Location/Qualifiers

/organism="Physcomitrella patens"
 /db_xref="taxon:3218"
 /clone="PEP_SOURCE_ID:"
 /clone_1ib="Moss EST library PEP"
 /tissue_type="gametophore: 30 day old tissue,
 ammonium-grown"
 /lab_host="DH10B"

/note="Vector: PAMPI; Construction of the cDNA library was performed by Dr. W. Gregg Clark using a modification of the cDNA synthesis protocol developed in the laboratory of Dr. Michael Lovett by Dr. Yulia Korshunova (personal communication). First polyA + RNA was isolated from total gametophore RNA using oligo dT magnetic beads. Following this, first strand cDNA synthesis was performed on the bead-bound polyA + RNA, during which an oligonucleotide anchor sequence was incorporated onto the 5'-ends of the cDNA. PCR amplification was then used to synthesize the second strand, to amplify the double stranded DNA, and to incorporate dmp containing sequences into the ends of the double stranded cDNA. This DNA was size selected and cloned into PAMPI using the CloneAMP PAMPI System (Life Technologies, GibcoBRL) for cloning amplification products by a non-restriction site dependent process. The cloning was directional based on sequence asymmetry introduced at the ends during PCR amplification. The 3' cDNA ends are proximal to the NotI site of the multiple cloning site in PAMPI. This annealing mixture was transformed into chemically competent DH10B cells and selected for ampicillin resistant growth. The resulting clones (about 330,000) were pooled to make the library."

BASE COUNT

31 a 11 c 15 g 26 t

ORIGIN

Query Match 55.2%; Score 16; DB 10; Length 83;
 Best local Similarity 41.7%; Pred. No. 5.7e+04;
 Matches 10; Conservative 9; Mismatches 5; Indels 0; Gaps 0;

6 uucuuuuuagaccacccaaagcgu 29
 :::::|||||
 37 TTTTGTGTAATCCCAAGACT 14

RESULT 11

BE959933

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

601654678R1 NIH_MGC_57 Homo sapiens cDNA clone IMAGE:3839754 3',
 mRNA sequence.
 BE959933
 BE959933.2 GI:11776130
 EST.
 human.
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 1 (bases 1 to 90)
 NIH-MGC http://mgs.nci.nih.gov/.
 National Institutes of Health, Mammalian Gene Collection (MGC)
 Unpublished (1999)
 On Oct 3, 2000 this sequence version replaced gi:10570638.
 Contact: Robert Strausberg, Ph.D.
 Email: cgabbs-r@mail.nih.gov

FEATURES

source

1. 90

Location/Qualifiers

/organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:3839754"
 /clone_1ib="NIH_MGC_57"
 /tissue_type="gliblastoma"
 /lab_host="DH10B (T1 phage-resistant)"
 /note="Organ: brain; Vector: pCMV-11B (Clontech); Site: 1; SfiI (ggcgccggcgcc); Site: 2; SfiI (ggcgccattggcgcc); Double-stranded cDNA was prepared from cell line RNA. 5' and 3' adaptors were used in cloning as follows: 5' adaptor sequence: 5'-ATCTGAGAGGCGCGCGCGCATG-dT(30)BN-3' (where B = A, C, or G and N = A, C, G, or T). Average insert size 1.55 kb (range 0.9-4.0 kb). 12/15 colonies contained inserts by PCR. This library was enriched for full-length clones and was constructed by Clontech Laboratories (Palo Alto, CA)."

High quality sequence stop: 19
 Plate: L10M528 row: k column: 19
 http://image.llnl.gov
 found through the I.M.A.G.E. Consortium/LLNL at:

BASE COUNT

21 a 11 c 14 g 44 t

ORIGIN

Query Match 55.2%; Score 16; DB 10; Length 90;
 Best local Similarity 50.0%; Pred. No. 5.7e+04;
 Matches 12; Conservative 7; Mismatches 5; Indels 0; Gaps 0;

QY 1 aaagaauuuuuuagaccacccaa 24
 |||:::|||||
 Db 38 AAAAATTTTGTGAAACCCCA 61

RESULT 12

A1824019/C

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

58 bp mRNA linear EST 21-DEC-1999
 wj29f03.x1 NCI-CGAP_K1d12 Homo sapiens cDNA clone IMAGE:2404253 3',
 similar to TR:070278 070278 MULTIPLE ENDOCRINE NEOPLASIA TYPE 1
 CANDIDATE PROTEIN NUMBER 18. ; mRNA sequence.
 A1824019
 A1824019.1 GI:5444690
 EST.
 human.
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 1 (bases 1 to 58)
 NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
 National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index
 Unpublished (1997)
 Contact: Robert Strausberg, Ph.D.
 Email: cgabbs-r@mail.nih.gov
 Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
 Emmert-Buck, M.D., Ph.D.
 CDNA Library Preparation: M. Bento Soares, Ph.D.
 DNA Sequencing by: Washington University Genome Sequencing Center
 Clone distribution: NCI-CGAP clone distribution information can be
 found through the I.M.A.G.E. Consortium/LLNL at:
 www-bio.llnl.gov/dbp/image/image.html

Trace considered overall poor quality
 Insert Length: 806 Std Error: 0.00
 Seq primer: -40UP from gibco

High quality sequence stop: 1.

FEATURES
source1. .58
Location/Qualifiers

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_image="2404253"
/clone_lib="NCI_CGAP_K1d12"
/tissue_type="2 pooled tumors (clear cell type)"
/lab_host="DH10B"
/note="Organ: Kidney; Vector: pF73D-Pac (Pharmacia) with a modified polylinker; Site_1: Not I; Site_2: Eco RI; Plasmid DNA from the normalized library NCI_CGAP_K1d5 was prepared, and ss circles were made in vitro. Following HAP purification, this DNA was used as tracer in a subtractive hybridization reaction. The driver was PCR-amplified cDNAs from a pool of 5,000 clones made from the same library (clonids 1323912-1325831, 1471368-1472903 and 1492104-1493255). Subtraction by Bento Soares and M. Fatima Bonaldo."

BASE COUNT
ORIGIN

11 a 14 c 19 g 14 t

Query Match 54.5%; Score 15.8; DB 9; Length 58;
Best Local Similarity 44.4%; Pred. No. 7.3e+04;
Matches 12; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

Oy 3 agauucuuuuuagagcccaaggcu 29

Db 56 AGCTTTTTCAGAGCTCAAGAGCT 30

RESULT 13

LOCUS A2657549 76 bp DNA linear GSS 14-DEC-2000
DEFINITION 1M0533L18R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
ACCESSION A2657549
VERSION A2657549.1 GI:11794695
KEYWORDS GSS.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
REFERENCE 1 (bases 1 to 76)
AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duvall, B., Hamill, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly,
M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausern, A.
and Wright, D., Weiss, R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0533 row: L column: 18
Seq primer: CACACAGCAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 76.
Location/Qualifiers

FEATURES
source

1. .76
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone_image="UUGC1M0533L18"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/sex="Male"

/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: pMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pMD42 (9147321419b/AP129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor mouse DNA was annealed to
adaptor vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

BASE COUNT
ORIGIN

12 a 14 c 18 g 32 t

Query Match 54.5%; Score 15.8; DB 12; Length 76;
Best Local Similarity 44.4%; Pred. No. 6.9e+04;
Matches 12; Conservative 8; Mismatches 7; Indels 0; Gaps 0;

Oy 3 agauucuuuuuagagcccaaggcu 29

Db 43 AGTTCTTTTGAGAGCTCAAGAGCT 69

RESULT 14

LOCUS A1802260 37 bp mRNA linear EST 13-DEC-1999
DEFINITION t336907.x1 NCI_CGAP_Pan1 Homo sapiens cDNA clone IMAGE:2143644 3'
similar to TR:Q41120 HYDROXYPROLINE-RICH GLYCOPROTEIN ;
mRNA sequence.
ACCESSION A1802260
VERSION A1802260.1 GI:5367732
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 37)
AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strussberg, Ph.D.
Email: cga@bs-remail.nih.gov
Life Technologies catalog #: 11548-013
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LNL at:
www-bio.lnl.gov/dbtp/image/image.html

FEATURES
source

1. .37
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_image="2143644"
/clone_lib="NCI_CGAP_Pan1"
/tissue_type="adenocarcinoma"
/lab_host="DH10B"
/note="Organ: pancreas; Vector: pCMV-SPORT6; Site_1: SalI;
Site_2: NotI; Cloned unidirectionally. Primer: Oligo dT.

Average insert size 1.72 kb. Life Technologies catalog #:
11548-013"

BASE COUNT 6 a 17 c 3 g 11 t

adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

BASE COUNT 15 a 13 c 16 g 14 t

Query Match 53.8%; Score 15.6; DB 9; Length 37;
Best Local Similarity 50.0%; Pred. No. 3e+04;

Query Match 53.8%; Score 15.6; DB 12; Length 58;
Best Local Similarity 54.5%; Pred. No. 8.6e+04;

Matches 11; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

Matches 12; Conservative 6; Mismatches 4; Indels 0; Gaps 0;

QY 1 aaagaucuuuuuugaagccccc 22

QY 4 gaucuuuuuuugaagccccaag 25

Db 7 AAAATTTTGTGAGAGCCCC 28

Db 24 GTTCCCTTGTATCCCAAG 3

RESULT 15
AZ834846/c 58 bp DNA linear GSS 20-FEB-2001

Search completed: September 13, 2002, 12:36:36
Job time: 9967 sec

LOCUS 2M0117F18R Mouse 10kb plasmid UGCI1 library Mus musculus genomic

DEFINITION 2M0117F18R Mouse 10kb plasmid UGCI1 library Mus musculus genomic

ACCESSION AZ834846
VERSION 1
KEYWORDS GSS.

SOURCE house mouse.
ORGANISM Mus musculus

REFERENCE 1 (bases 1 to 58)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,
M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A.
and Wright,D., Weiss,R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts

JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA

Tel: 801 585 5606
Fax: 801 585 7177
Email: dtunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0117 row: F column: 18
Seq primer: CACACAGAAACAGCTATGACC
Class: plasmid ends

High quality sequence stop: 58.
Location/Qualifiers

1. 58

/organism="Mus musculus"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUGC2M0117F18"

/clone_lib="Mouse 10kb plasmid UGCI1 library"

/sex="Male"

/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"

/note="Vector: PMD42ny; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose/gel
electrophoresis. Vector DNA was prepared from a derivative
of PMD42 (g147321419b/AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to